{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "30ab066b",
   "metadata": {},
   "outputs": [],
   "source": [
    "base_url = \"https://serpapi.com/search?engine=google_patents\""
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "id": "39970520",
   "metadata": {},
   "outputs": [],
   "source": [
    "import os\n",
    "import requests\n",
    "import json\n",
    "from pprint import pprint\n",
    "from dotenv import load_dotenv\n",
    "load_dotenv()\n",
    "\n",
    "\n",
    "api_key = os.getenv(\"SERP_API_KEY\")\n",
    "if not api_key:\n",
    "    raise ValueError(\"API Key is not in environment variables\")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "id": "9e2848ff",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "API Key from env: a5990e6a315aba97140ab69e914f2675947c7be491cf3f97a85fc24ecfef3961\n"
     ]
    }
   ],
   "source": [
    "load_dotenv()  # This looks in the current folder\n",
    "print(\"API Key from env:\", os.getenv(\"SERP_API_KEY\"))\n",
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "id": "25be8fc5",
   "metadata": {},
   "outputs": [],
   "source": [
    "query = \"langgraph\"\n",
    "url = f\"https://serpapi.com/search?engine=google_patents&q={query}&api_key={api_key}\""
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "id": "ec7dbeca",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{'search_metadata': {'id': '687ecfa812eb14d90e9fcfcf', 'status': 'Success', 'json_endpoint': 'https://serpapi.com/searches/3e89de789691ab75/687ecfa812eb14d90e9fcfcf.json', 'created_at': '2025-07-21 23:39:20 UTC', 'processed_at': '2025-07-21 23:39:20 UTC', 'google_patents_url': 'https://patents.google.com/xhr/query?url=q%3Dlanggraph', 'raw_html_file': 'https://serpapi.com/searches/3e89de789691ab75/687ecfa812eb14d90e9fcfcf.html', 'prettify_html_file': 'https://serpapi.com/searches/3e89de789691ab75/687ecfa812eb14d90e9fcfcf.prettify', 'total_time_taken': 0.66}, 'search_parameters': {'engine': 'google_patents', 'q': 'langgraph'}, 'search_information': {'total_results': 31, 'total_pages': 4, 'page_number': 1}, 'organic_results': [{'position': 1, 'rank': 0, 'patent_id': 'patent/CN119226078A/en', 'patent_link': 'https://patents.google.com/patent/CN119226078A/en', 'serpapi_link': 'https://serpapi.com/search.json?engine=google_patents_details&patent_id=patent%2FCN119226078A%2Fen', 'title': 'Device analysis method, system, device and storage medium based on multi-agent', 'snippet': '… , is responsible for receiving user input, and routes tasks to the corresponding task agent for processing according to an understanding of the language. In some embodiments, the supervisor agent-task agent architecture may be built and developed through the open source agent framework LANGGRAPH.', 'priority_date': '2024-08-22', 'filing_date': '2024-08-22', 'publication_date': '2024-12-31', 'inventor': '黎健勇', 'assignee': '广州市申迪计算机系统有限公司', 'publication_number': 'CN119226078A', 'language': 'en', 'pdf': 'https://patentimages.storage.googleapis.com/fc/72/75/ca2b55e9d3bc0a/CN119226078A.pdf', 'country_status': {'CN': 'ACTIVE'}}, {'position': 2, 'rank': 1, 'patent_id': 'patent/SA520412545B1/en', 'patent_link': 'https://patents.google.com/patent/SA520412545B1/en', 'serpapi_link': 'https://serpapi.com/search.json?engine=google_patents_details&patent_id=patent%2FSA520412545B1%2Fen', 'title': 'Systems and methods for evaluation of formation shear slowness', 'snippet': 'Systems and methods for determining a shear wave slowness may include emitting an emitted acoustic wave within a borehole from an acoustic tool. A return acoustic wave may be detected via one or more sensors. The return acoustic wave may be generated when the emitted acoustic wave interacts with a …', 'priority_date': '2018-01-31', 'filing_date': '2020-07-29', 'publication_date': '2023-03-15', 'inventor': 'ديجر إفجينيا', 'assignee': 'شلمبيرجر تكنولوجي بي. في.', 'publication_number': 'SA520412545B1', 'language': 'en', 'pdf': 'https://patentimages.storage.googleapis.com/bd/ea/10/edb3cb7ca2a113/SA520412545B1.pdf', 'country_status': {'WO': 'ACTIVE', 'US': 'ACTIVE', 'SA': 'UNKNOWN'}}, {'position': 3, 'rank': 2, 'patent_id': 'patent/US6311190B1/en', 'patent_link': 'https://patents.google.com/patent/US6311190B1/en', 'serpapi_link': 'https://serpapi.com/search.json?engine=google_patents_details&patent_id=patent%2FUS6311190B1%2Fen', 'title': 'System for conducting surveys in different languages over a network with survey …', 'snippet': 'A system for conducting surveys to voters in multiple different languages and registering voters is provided over a network, such as the Internet. The system includes a programmed computer system representing at least one network server which provides an addressable voting site and registration …', 'priority_date': '1999-02-02', 'filing_date': '1999-02-02', 'grant_date': '2001-10-30', 'publication_date': '2001-10-30', 'inventor': 'Leonard Robert Bayer', 'assignee': 'Harris Interactive Inc.', 'publication_number': 'US6311190B1', 'language': 'en', 'thumbnail': 'https://patentimages.storage.googleapis.com/db/82/78/478f71a5a7c554/US6311190-drawings-page-3.png', 'pdf': 'https://patentimages.storage.googleapis.com/43/ed/52/f5884040136ee9/US6311190.pdf', 'figures': [{'thumbnail': 'https://patentimages.storage.googleapis.com/d7/13/30/6d2e8246244f9e/US6311190-drawings-page-3.png', 'full': 'https://patentimages.storage.googleapis.com/7a/61/e8/dff8e3236a799a/US6311190-drawings-page-3.png'}, {'thumbnail': 'https://patentimages.storage.googleapis.com/a3/fc/b1/b77552bf859f4f/US6311190-drawings-page-4.png', 'full': 'https://patentimages.storage.googleapis.com/d9/73/77/99d69e3a1149ed/US6311190-drawings-page-4.png'}, {'thumbnail': 'https://patentimages.storage.googleapis.com/6b/88/dd/3f6dc12a72b2b7/US6311190-drawings-page-5.png', 'full': 'https://patentimages.storage.googleapis.com/73/aa/83/9661bfd7434d48/US6311190-drawings-page-5.png'}, {'thumbnail': 'https://patentimages.storage.googleapis.com/f3/56/97/744d1922ac54cb/US6311190-drawings-page-6.png', 'full': 'https://patentimages.storage.googleapis.com/10/c1/2c/be01404ba7ddfd/US6311190-drawings-page-6.png'}, {'thumbnail': 'https://patentimages.storage.googleapis.com/f6/9f/c5/12465718dd9742/US6311190-drawings-page-7.png', 'full': 'https://patentimages.storage.googleapis.com/6c/e6/1d/478a3b6569edbf/US6311190-drawings-page-7.png'}, {'thumbnail': 'https://patentimages.storage.googleapis.com/5c/e0/fe/b05a85d5156bed/US6311190-drawings-page-8.png', 'full': 'https://patentimages.storage.googleapis.com/85/7b/e4/0283c5700498f1/US6311190-drawings-page-8.png'}, {'thumbnail': 'https://patentimages.storage.googleapis.com/ae/ec/ad/613f1b27cabb9d/US6311190-drawings-page-9.png', 'full': 'https://patentimages.storage.googleapis.com/81/08/6e/974c518b9d9e39/US6311190-drawings-page-9.png'}, {'thumbnail': 'https://patentimages.storage.googleapis.com/09/83/88/a0f0cd78f7e5d5/US6311190-drawings-page-10.png', 'full': 'https://patentimages.storage.googleapis.com/cd/5d/f3/dc9e906268554a/US6311190-drawings-page-10.png'}, {'thumbnail': 'https://patentimages.storage.googleapis.com/62/95/b9/f623068247041a/US6311190-drawings-page-11.png', 'full': 'https://patentimages.storage.googleapis.com/e6/95/54/90b6dc055bee99/US6311190-drawings-page-11.png'}, {'thumbnail': 'https://patentimages.storage.googleapis.com/f3/39/85/52a960a0132e23/US6311190-drawings-page-12.png', 'full': 'https://patentimages.storage.googleapis.com/63/b0/fa/6f9fc9c3a67c90/US6311190-drawings-page-12.png'}, {'thumbnail': 'https://patentimages.storage.googleapis.com/78/27/d9/9472b9166f21cf/US6311190-drawings-page-13.png', 'full': 'https://patentimages.storage.googleapis.com/ec/91/9c/5578dc24b59f4e/US6311190-drawings-page-13.png'}, {'thumbnail': 'https://patentimages.storage.googleapis.com/1d/bf/46/445949ba268d44/US6311190-drawings-page-14.png', 'full': 'https://patentimages.storage.googleapis.com/16/7b/7b/a75cb3f7e00a44/US6311190-drawings-page-14.png'}, {'thumbnail': 'https://patentimages.storage.googleapis.com/3e/d8/ad/9a996da301e4d9/US6311190-drawings-page-15.png', 'full': 'https://patentimages.storage.googleapis.com/94/38/87/d1cc158ba2889a/US6311190-drawings-page-15.png'}, {'thumbnail': 'https://patentimages.storage.googleapis.com/e6/ca/bb/3522fb546a3cdd/US6311190-drawings-page-16.png', 'full': 'https://patentimages.storage.googleapis.com/2d/27/a5/0a1a8d0b1cda1f/US6311190-drawings-page-16.png'}, {'thumbnail': 'https://patentimages.storage.googleapis.com/ac/98/82/31e62a68ace870/US6311190-drawings-page-17.png', 'full': 'https://patentimages.storage.googleapis.com/f8/f7/85/95795e3b9b33fd/US6311190-drawings-page-17.png'}, {'thumbnail': 'https://patentimages.storage.googleapis.com/79/9a/a2/faaa39899c010a/US6311190-drawings-page-18.png', 'full': 'https://patentimages.storage.googleapis.com/fb/21/e8/2ff72d9a5e10b3/US6311190-drawings-page-18.png'}, {'thumbnail': 'https://patentimages.storage.googleapis.com/8c/a2/2c/a6f61f1077dc81/US6311190-drawings-page-19.png', 'full': 'https://patentimages.storage.googleapis.com/b3/0a/63/50f538a02889e5/US6311190-drawings-page-19.png'}, {'thumbnail': 'https://patentimages.storage.googleapis.com/c9/ba/45/7c184f7fedef2a/US6311190-drawings-page-20.png', 'full': 'https://patentimages.storage.googleapis.com/96/8e/14/9e5f7a41dbdde0/US6311190-drawings-page-20.png'}, {'thumbnail': 'https://patentimages.storage.googleapis.com/ca/bf/17/0ca2307c6506bd/US6311190-drawings-page-21.png', 'full': 'https://patentimages.storage.googleapis.com/81/d4/0e/f9f34a32821fb3/US6311190-drawings-page-21.png'}, {'thumbnail': 'https://patentimages.storage.googleapis.com/e5/18/d9/eaae04df313d5f/US6311190-drawings-page-22.png', 'full': 'https://patentimages.storage.googleapis.com/48/58/03/cb257cd4ed0a55/US6311190-drawings-page-22.png'}, {'thumbnail': 'https://patentimages.storage.googleapis.com/57/2a/0b/faabe241bd794b/US6311190-drawings-page-23.png', 'full': 'https://patentimages.storage.googleapis.com/04/f4/53/92f6b6aeb3b8f0/US6311190-drawings-page-23.png'}, {'thumbnail': 'https://patentimages.storage.googleapis.com/a0/b5/65/1347ee97756eb9/US6311190-drawings-page-24.png', 'full': 'https://patentimages.storage.googleapis.com/31/f2/01/31faf47ee4a295/US6311190-drawings-page-24.png'}, {'thumbnail': 'https://patentimages.storage.googleapis.com/8d/a9/af/edcecb62945248/US6311190-drawings-page-25.png', 'full': 'https://patentimages.storage.googleapis.com/22/09/ae/305eb9263fd779/US6311190-drawings-page-25.png'}, {'thumbnail': 'https://patentimages.storage.googleapis.com/6d/75/c3/42c6b7b1f5d910/US6311190-drawings-page-26.png', 'full': 'https://patentimages.storage.googleapis.com/60/96/fe/7e0273ee2eb135/US6311190-drawings-page-26.png'}, {'thumbnail': 'https://patentimages.storage.googleapis.com/a0/45/ec/12750a112e4778/US6311190-drawings-page-27.png', 'full': 'https://patentimages.storage.googleapis.com/ed/58/5c/fdaaf08ece6f8d/US6311190-drawings-page-27.png'}, {'thumbnail': 'https://patentimages.storage.googleapis.com/19/f7/57/d881fb51d79327/US6311190-drawings-page-28.png', 'full': 'https://patentimages.storage.googleapis.com/fe/75/52/87296369c6975c/US6311190-drawings-page-28.png'}, {'thumbnail': 'https://patentimages.storage.googleapis.com/c2/9d/17/86a6c75d1d9c51/US6311190-drawings-page-29.png', 'full': 'https://patentimages.storage.googleapis.com/9d/67/a9/822590c9c43552/US6311190-drawings-page-29.png'}], 'country_status': {'WO': 'ACTIVE', 'EP': 'NOT_ACTIVE', 'US': 'NOT_ACTIVE', 'AU': 'ACTIVE', 'CA': 'NOT_ACTIVE'}}, {'position': 4, 'rank': 3, 'patent_id': 'patent/CN119761795A/en', 'patent_link': 'https://patents.google.com/patent/CN119761795A/en', 'serpapi_link': 'https://serpapi.com/search.json?engine=google_patents_details&patent_id=patent%2FCN119761795A%2Fen', 'title': 'A LangGraph-based intelligent detection and maintenance method for aviation …', 'snippet': '7. The intelligent detection and maintenance method for aviation equipment based on LangGraph as described in claim 1 is characterized in that step S5 includes: defining nodes and connections between nodes in LangGraph, wherein the nodes are processing units in the workflow, and each node is a …', 'priority_date': '2024-12-20', 'filing_date': '2024-12-20', 'publication_date': '2025-04-04', 'inventor': '赵华蕾', 'assignee': '上海埃威信息科技有限公司', 'publication_number': 'CN119761795A', 'language': 'en', 'pdf': 'https://patentimages.storage.googleapis.com/cc/c1/28/fe8d3b8e7bf836/CN119761795A.pdf', 'country_status': {'CN': 'ACTIVE'}}, {'position': 5, 'rank': 4, 'patent_id': 'patent/CN119626459A/en', 'patent_link': 'https://patents.google.com/patent/CN119626459A/en', 'serpapi_link': 'https://serpapi.com/search.json?engine=google_patents_details&patent_id=patent%2FCN119626459A%2Fen', 'title': 'Agent-based conversation method and device, storage medium, and electronic …', 'snippet': '3. The method according to claim 1, wherein using the plurality of agents to construct a dynamic LangGraph comprises: Determining logical relationships among the plurality of agents; A dynamic LangGraph is constructed with each of the intelligent agents as a node and each of the logical …', 'priority_date': '2025-02-17', 'filing_date': '2025-02-17', 'publication_date': '2025-03-14', 'inventor': '杨胤', 'assignee': '北京轻松怡康信息技术有限公司', 'publication_number': 'CN119626459A', 'language': 'en', 'pdf': 'https://patentimages.storage.googleapis.com/e6/03/7c/8e3feab873651a/CN119626459A.pdf', 'country_status': {'CN': 'ACTIVE'}}, {'position': 6, 'rank': 5, 'patent_id': 'patent/KR102829171B1/en', 'patent_link': 'https://patents.google.com/patent/KR102829171B1/en', 'serpapi_link': 'https://serpapi.com/search.json?engine=google_patents_details&patent_id=patent%2FKR102829171B1%2Fen', 'title': 'Information system and development method for the real estate domain using …', 'snippet': 'The present invention is also preferably a real estate information provision system characterized in that, in addition to the above-described features, the intent classification module is configured based on the LangGraph of the LangChain framework and performs the function of classifying queries …', 'filing_date': '2025-04-29', 'grant_date': '2025-07-10', 'publication_date': '2025-07-10', 'inventor': '전원표', 'assignee': '(주)바이브컴퍼니', 'publication_number': 'KR102829171B1', 'language': 'en', 'pdf': 'https://patentimages.storage.googleapis.com/cc/15/61/50e7503b0a0f4e/KR102829171B1.pdf'}, {'position': 7, 'rank': 6, 'patent_id': 'patent/CN120165927A/en', 'patent_link': 'https://patents.google.com/patent/CN120165927A/en', 'serpapi_link': 'https://serpapi.com/search.json?engine=google_patents_details&patent_id=patent%2FCN120165927A%2Fen', 'title': 'Initial reconnaissance method and device for network space asset vulnerability …', 'snippet': 'The task decision agent generates a plurality of different execution paths for the same task based on the asynchronous capability of LANGGRAPH frames, and the task is processed by the plurality of agents in parallel or in parallel, so that the plurality of execution paths of the task are covered …', 'priority_date': '2025-03-19', 'filing_date': '2025-03-19', 'publication_date': '2025-06-17', 'inventor': '陶锐', 'assignee': '中国电子科技集团公司第三十研究所', 'publication_number': 'CN120165927A', 'language': 'en', 'pdf': 'https://patentimages.storage.googleapis.com/7b/18/df/650d2f897f8a0a/CN120165927A.pdf', 'country_status': {'CN': 'ACTIVE'}}, {'position': 8, 'rank': 7, 'patent_id': 'patent/CN120216167A/en', 'patent_link': 'https://patents.google.com/patent/CN120216167A/en', 'serpapi_link': 'https://serpapi.com/search.json?engine=google_patents_details&patent_id=patent%2FCN120216167A%2Fen', 'title': 'A task processing method, device and system', 'snippet': 'In the prior art, a planner agent (PLANNER AGENT) and LANGGRAPH are adopted to process the tasks, wherein the PLANNER AGENT disassembles the complex tasks into a plurality of subtasks through optimizing the planning and task execution processes, and then sequentially or batchly executes the …', 'priority_date': '2025-02-21', 'filing_date': '2025-02-21', 'publication_date': '2025-06-27', 'inventor': '李芮', 'assignee': '阿里巴巴（中国）有限公司', 'publication_number': 'CN120216167A', 'language': 'en', 'pdf': 'https://patentimages.storage.googleapis.com/08/63/8d/5f7278c189cc3f/CN120216167A.pdf', 'country_status': {'CN': 'ACTIVE'}}, {'position': 9, 'rank': 8, 'patent_id': 'patent/CN119652567A/en', 'patent_link': 'https://patents.google.com/patent/CN119652567A/en', 'serpapi_link': 'https://serpapi.com/search.json?engine=google_patents_details&patent_id=patent%2FCN119652567A%2Fen', 'title': 'An automatic construction system for honey hole scenes based on large models', 'snippet': '3. According to the large model-based honey hole scene automatic construction system of claim 1, it is characterized in that a plurality of said intelligent agents are connected through LangGraph as an information transmission platform to achieve information collaboration between each other, …', 'priority_date': '2024-11-21', 'filing_date': '2024-11-21', 'publication_date': '2025-03-18', 'inventor': '田志宏', 'assignee': '广州大学', 'publication_number': 'CN119652567A', 'language': 'en', 'pdf': 'https://patentimages.storage.googleapis.com/e0/33/34/b2c12fdbf21a8f/CN119652567A.pdf', 'country_status': {'CN': 'ACTIVE'}}, {'position': 10, 'rank': 9, 'patent_id': 'patent/CN118568250A/en', 'patent_link': 'https://patents.google.com/patent/CN118568250A/en', 'serpapi_link': 'https://serpapi.com/search.json?engine=google_patents_details&patent_id=patent%2FCN118568250A%2Fen', 'title': 'A method, device, medium and equipment for implementing callback function based …', 'snippet': \"LangGraph is a framework for building stateful and multi-role Agents applications. It is not a new framework independent of Langchain, but an extension library built on Langchain that can work seamlessly with Langchain's existing chains (Chains), LangChain Expression Language (LCEL), etc. LangGraph …\", 'priority_date': '2024-08-01', 'filing_date': '2024-08-01', 'publication_date': '2024-08-30', 'inventor': '刘非', 'assignee': '中汽数据(天津)有限公司', 'publication_number': 'CN118568250A', 'language': 'en', 'pdf': 'https://patentimages.storage.googleapis.com/66/7b/d2/8a96ef803b994a/CN118568250A.pdf', 'country_status': {'CN': 'ACTIVE'}}], 'summary': {'assignee': [{'key': 'Total', 'percentage': 100.0, 'frequency': [{'year_range': '2025-2028', 'percentage': 1.0}, {'year_range': '2022-2025', 'percentage': 1.5}, {'year_range': '2019-2022', 'percentage': 0.2}, {'year_range': '1998-2001', 'percentage': 0.1}, {'year_range': '1914-1917', 'percentage': 0.1}, {'year_range': '1911-1914', 'percentage': 0.2}]}, {'key': '广东数业智能科技有限公司', 'percentage': 9.6, 'frequency': [{'year_range': '2022-2025', 'percentage': 0.3}]}, {'key': '杭州市滨江区浙工大人工智能创新研究院', 'percentage': 9.6, 'frequency': [{'year_range': '2025-2028', 'percentage': 0.3}]}, {'key': '浙江工业大学', 'percentage': 9.6, 'frequency': [{'year_range': '2025-2028', 'percentage': 0.3}]}, {'key': '阿里巴巴（中国）有限公司', 'percentage': 6.4, 'frequency': [{'year_range': '2025-2028', 'percentage': 0.1}, {'year_range': '2022-2025', 'percentage': 0.1}]}, {'key': '(주)바이브컴퍼니', 'percentage': 6.4, 'frequency': [{'year_range': '2025-2028', 'percentage': 0.2}]}, {'key': 'Ferdinand C Bretsnyder', 'percentage': 3.2, 'frequency': [{'year_range': '1911-1914', 'percentage': 0.1}]}, {'key': '中国移动通信集团浙江有限公司', 'percentage': 3.2, 'frequency': [{'year_range': '2022-2025', 'percentage': 0.1}]}, {'key': '上海埃威信息科技有限公司', 'percentage': 3.2, 'frequency': [{'year_range': '2022-2025', 'percentage': 0.1}]}, {'key': '成都数之联科技股份有限公司', 'percentage': 3.2, 'frequency': [{'year_range': '2025-2028', 'percentage': 0.1}]}, {'key': '优酷文化科技(北京)有限公司', 'percentage': 3.2, 'frequency': [{'year_range': '2022-2025', 'percentage': 0.1}]}, {'key': '佳都科技集团股份有限公司', 'percentage': 3.2, 'frequency': [{'year_range': '2022-2025', 'percentage': 0.1}]}, {'key': 'Landers Frary & Clark', 'percentage': 3.2, 'frequency': [{'year_range': '1914-1917', 'percentage': 0.1}]}, {'key': 'John W Porter', 'percentage': 3.2, 'frequency': [{'year_range': '1911-1914', 'percentage': 0.1}]}, {'key': '广州市申迪计算机系统有限公司', 'percentage': 3.2, 'frequency': [{'year_range': '2022-2025', 'percentage': 0.1}]}, {'key': '中国航空无线电电子研究所', 'percentage': 3.2, 'frequency': [{'year_range': '2022-2025', 'percentage': 0.1}]}, {'key': '中国移动(浙江)创新研究院有限公司', 'percentage': 3.2, 'frequency': [{'year_range': '2022-2025', 'percentage': 0.1}]}, {'key': 'Henry W Hamilton', 'percentage': 3.2, 'frequency': [{'year_range': '1911-1914', 'percentage': 0.1}]}, {'key': '广州佳都城轨智慧运维服务有限公司', 'percentage': 3.2, 'frequency': [{'year_range': '2022-2025', 'percentage': 0.1}]}, {'key': 'Harris Interactive Inc.', 'percentage': 3.2, 'frequency': [{'year_range': '1998-2001', 'percentage': 0.1}]}], 'inventor': [{'key': 'Total', 'percentage': 100.0, 'frequency': [{'year_range': '2025-2028', 'percentage': 1.0}, {'year_range': '2022-2025', 'percentage': 1.5}, {'year_range': '2019-2022', 'percentage': 0.2}, {'year_range': '1998-2001', 'percentage': 0.1}, {'year_range': '1914-1917', 'percentage': 0.1}, {'year_range': '1911-1914', 'percentage': 0.2}]}, {'key': '代斌', 'percentage': 9.6, 'frequency': [{'year_range': '2025-2028', 'percentage': 0.3}]}, {'key': '李楚怡', 'percentage': 9.6, 'frequency': [{'year_range': '2022-2025', 'percentage': 0.3}]}, {'key': '葛俊彦', 'percentage': 9.6, 'frequency': [{'year_range': '2022-2025', 'percentage': 0.3}]}, {'key': '唐天驰', 'percentage': 9.6, 'frequency': [{'year_range': '2022-2025', 'percentage': 0.3}]}, {'key': '吕广平', 'percentage': 9.6, 'frequency': [{'year_range': '2025-2028', 'percentage': 0.3}]}, {'key': '刘昌松', 'percentage': 9.6, 'frequency': [{'year_range': '2022-2025', 'percentage': 0.3}]}, {'key': '陈铁明', 'percentage': 9.6, 'frequency': [{'year_range': '2025-2028', 'percentage': 0.3}]}, {'key': '吕明琪', 'percentage': 9.6, 'frequency': [{'year_range': '2025-2028', 'percentage': 0.3}]}, {'key': '黄明贵', 'percentage': 9.6, 'frequency': [{'year_range': '2022-2025', 'percentage': 0.3}]}, {'key': '王飞', 'percentage': 9.6, 'frequency': [{'year_range': '2025-2028', 'percentage': 0.3}]}, {'key': '朱添田', 'percentage': 9.6, 'frequency': [{'year_range': '2025-2028', 'percentage': 0.3}]}, {'key': '张汝民', 'percentage': 9.6, 'frequency': [{'year_range': '2022-2025', 'percentage': 0.3}]}, {'key': '전원표', 'percentage': 6.4, 'frequency': [{'year_range': '2025-2028', 'percentage': 0.2}]}, {'key': '이민주', 'percentage': 6.4, 'frequency': [{'year_range': '2025-2028', 'percentage': 0.2}]}, {'key': '陈可', 'percentage': 3.2, 'frequency': [{'year_range': '2022-2025', 'percentage': 0.1}]}, {'key': 'John W Porter', 'percentage': 3.2, 'frequency': [{'year_range': '1911-1914', 'percentage': 0.1}]}, {'key': '邢宇强', 'percentage': 3.2, 'frequency': [{'year_range': '2022-2025', 'percentage': 0.1}]}, {'key': '邢骏洋', 'percentage': 3.2, 'frequency': [{'year_range': '2022-2025', 'percentage': 0.1}]}, {'key': '董自然', 'percentage': 3.2, 'frequency': [{'year_range': '2022-2025', 'percentage': 0.1}]}], 'cpc': [{'key': 'Total', 'percentage': 100.0, 'frequency': [{'year_range': '2025-2028', 'percentage': 1.0}, {'year_range': '2022-2025', 'percentage': 1.5}, {'year_range': '2019-2022', 'percentage': 0.2}, {'year_range': '1998-2001', 'percentage': 0.1}, {'year_range': '1914-1917', 'percentage': 0.1}, {'year_range': '1911-1914', 'percentage': 0.2}]}, {'key': 'G06F', 'percentage': 25.8, 'frequency': [{'year_range': '2025-2028', 'percentage': 0.2}, {'year_range': '2022-2025', 'percentage': 0.6}]}, {'key': 'G06Q', 'percentage': 12.9, 'frequency': [{'year_range': '2025-2028', 'percentage': 0.3}, {'year_range': '1998-2001', 'percentage': 0.1}]}, {'key': 'G06N', 'percentage': 12.9, 'frequency': [{'year_range': '2022-2025', 'percentage': 0.4}]}, {'key': 'Y02D', 'percentage': 9.6, 'frequency': [{'year_range': '2025-2028', 'percentage': 0.1}, {'year_range': '2022-2025', 'percentage': 0.2}]}, {'key': 'G10L', 'percentage': 6.4, 'frequency': [{'year_range': '2022-2025', 'percentage': 0.1}, {'year_range': '2019-2022', 'percentage': 0.1}]}, {'key': 'F23L', 'percentage': 3.2, 'frequency': [{'year_range': '1911-1914', 'percentage': 0.1}]}, {'key': 'G16H', 'percentage': 3.2, 'frequency': [{'year_range': '2025-2028', 'percentage': 0.1}]}, {'key': 'Y02A', 'percentage': 3.2, 'frequency': [{'year_range': '2022-2025', 'percentage': 0.1}]}, {'key': 'Y02P', 'percentage': 3.2, 'frequency': [{'year_range': '2022-2025', 'percentage': 0.1}]}, {'key': 'Y10S', 'percentage': 3.2, 'frequency': [{'year_range': '1998-2001', 'percentage': 0.1}]}, {'key': 'G01W', 'percentage': 3.2, 'frequency': [{'year_range': '2022-2025', 'percentage': 0.1}]}, {'key': 'F23D', 'percentage': 3.2, 'frequency': [{'year_range': '1911-1914', 'percentage': 0.1}]}, {'key': 'G01V', 'percentage': 3.2, 'frequency': [{'year_range': '2019-2022', 'percentage': 0.1}]}, {'key': 'F25C', 'percentage': 3.2, 'frequency': [{'year_range': '1914-1917', 'percentage': 0.1}]}]}, 'pagination': {'current': 1, 'next': 'https://patents.google.com/xhr/query?url=q%3Dlanggraph%26page%3D2'}, 'serpapi_pagination': {'current': 1, 'next': 'https://serpapi.com/search.json?engine=google_patents&page=2&q=langgraph'}}\n"
     ]
    }
   ],
   "source": [
    "response = requests.get(url)\n",
    "if response.status_code == 200:\n",
    "    data = response.json()\n",
    "    print(data)\n",
    "    patents = data.get(\"organic_results\",[])\n",
    "    with open(\"files/patents.json\",\"w\") as file:\n",
    "        json.dump(patents,file,indent = 4)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "id": "57005b29",
   "metadata": {},
   "outputs": [],
   "source": [
    "patent_url = \"https://serpapi.com/search.json?engine=google_patents_details&patent_id=patent%2FCN119226078A%2Fen&api_key=\" + api_key\n",
    "patents_response = requests.get(patent_url)\n",
    "if patents_response.status_code ==200:\n",
    "    patent_data = patents_response.json()\n",
    "    \n",
    "    with open('files/patent_details.json',\"w\") as file:\n",
    "        json.dump(patent_data,file,indent = 4)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "id": "4628a538",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "dict_keys(['search_metadata', 'search_parameters', 'title', 'type', 'pdf', 'publication_number', 'country', 'prior_art_keywords', 'prior_art_date', 'application_number', 'inventors', 'assignees', 'priority_date', 'filing_date', 'publication_date', 'worldwide_applications', 'events', 'external_links', 'classifications', 'abstract', 'abstract_original', 'description_link', 'claims', 'priority_applications', 'applications_claiming_priority', 'family_id', 'patent_citations', 'cited_by', 'similar_documents', 'legal_events'])"
      ]
     },
     "execution_count": 15,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "patent_data.keys()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 18,
   "id": "c9b1d2a5",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "('The embodiments of the present application provide a multi-agent-based '\n",
      " 'device analysis method, system, device and storage medium, which belongs to '\n",
      " 'the field of artificial intelligence technology. The method first obtains '\n",
      " 'the user question text about the device analysis, and uses the large '\n",
      " 'language model of the supervisor agent to perform task decomposition and '\n",
      " 'planning on the user question text to determine the target subtask and the '\n",
      " 'task agent corresponding to the target subtask, and then uses the supervisor '\n",
      " 'agent to call the application program interface of the task agent to execute '\n",
      " 'the target subtask to obtain task feedback. The large language model '\n",
      " 'generates the device analysis results based on the task feedback and feeds '\n",
      " 'them back to the user. The present application completes various device '\n",
      " 'analysis tasks through the cooperation of multiple agents. The supervisor '\n",
      " 'agent-task agent architecture can conveniently expand the device analysis '\n",
      " \"tasks and flexibly handle the user's device analysis needs.\")\n"
     ]
    }
   ],
   "source": [
    "# fetch abstract data\n",
    "pprint(patent_data.get(\"abstract\",\"\"))\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 20,
   "id": "72eca1cb",
   "metadata": {},
   "outputs": [],
   "source": [
    "# print(patent_data.get(\"abstract\",\"\"))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 24,
   "id": "38dbb1dc",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "('The invention relates to freeze-dried particles comprising ribonucleic acid '\n",
      " '(RNA) and methods for the preparation of said particles. The invention '\n",
      " 'further relates to the use of said particles in methods for the detection of '\n",
      " 'nucleic acid as well as test-kits for the detection of nucleic acid '\n",
      " 'comprising said particles. By freeze-drying RNA, a stable product can be '\n",
      " 'obtained that can be preserved for a long time without loosing its '\n",
      " 'structure. The freeze-dried RNA-containing particles according to the '\n",
      " 'invention are therefore very useful alternatives for, for example, presently '\n",
      " 'used RNA-containing reagent solutions. The particles according to the '\n",
      " 'present invention are dry and therefore almost insensitive to various '\n",
      " 'degradation processes.')\n",
      "\n",
      "========================================\n",
      "\n",
      "('Dispersibility of a respirable powder, administrable by inhalation, is '\n",
      " 'increased by including a pharmaceutically acceptable water-soluble '\n",
      " 'polypeptide.')\n",
      "\n",
      "========================================\n",
      "\n",
      "('The present invention relates to a pharmaceutical composition comprising a '\n",
      " 'modified mRNA that is stabilised by sequence modifications and optimised for '\n",
      " 'translation. The pharmaceutical composition according to the invention is '\n",
      " 'particularly well suited for use as an inoculating agent, as well as a '\n",
      " 'therapeutic agent for tissue regeneration. In addition, a process is '\n",
      " 'described for determining sequence modifications that promote stabilisation '\n",
      " 'and translational efficiency of modified mRNA of the invention.')\n",
      "\n",
      "========================================\n",
      "\n",
      "('The present invention relates to a pharmaceutical composition comprising at '\n",
      " 'least one mRNA comprising at least one coding region for at least one '\n",
      " 'antigen from a tumour, in combination with an aqueous solvent and preferably '\n",
      " 'a cytokine, e.g. GM-CSF, and a process for the preparation of the '\n",
      " 'pharmaceutical composition. The pharmaceutical composition according to the '\n",
      " 'invention is used in particular for therapy and/or prophylaxis against '\n",
      " 'cancer.')\n",
      "\n",
      "========================================\n",
      "\n",
      "('Recombinant nucleic acid molecules are described. The molecules have a '\n",
      " 'sequence or sequences encoding an antigen from Bacillus anthracis. Vectors '\n",
      " 'and compositions containing these molecules are also described. Methods for '\n",
      " 'eliciting an immune response using these molecules and compositions are also '\n",
      " 'described.')\n",
      "\n",
      "========================================\n",
      "\n",
      "('The present invention provides compositions comprising a conjugate of a '\n",
      " 'hapten with a carrier in an ordered and repetitive array, and methods of '\n",
      " 'making such compositions. The conjugates and compositions of the invention '\n",
      " 'may comprise a variety of haptens, including hormones, toxins and drugs, '\n",
      " 'especially drugs of addiction such as nicotine. Compositions and conjugates '\n",
      " 'of the invention are useful for inducing immune responses against haptens, '\n",
      " 'which can use useful in a variety of therapeutic, prophylactic and '\n",
      " 'diagnostic regimens. In certain embodiments, immune responses generated '\n",
      " 'using the conjugates, compositions and methods of the present invention are '\n",
      " 'useful to prevent or treat addiction to drugs of abuse and the resultant '\n",
      " 'diseases associated with drug addiction.')\n",
      "\n",
      "========================================\n",
      "\n",
      "('The present invention relates to an immunostimulating agent comprising at '\n",
      " 'least one chemically modified RNA. The invention furthermore relates to a '\n",
      " 'vaccine which comprises at least one antigen in combination with the '\n",
      " 'immunostimulating agent. The immunostimulating agent according to the '\n",
      " 'invention and the vaccine according to the invention are employed in '\n",
      " 'particular against infectious diseases or cancer diseases.')\n",
      "\n",
      "========================================\n",
      "\n",
      "('A method of manufacturing heat-sensitive pharmaceutical powder is disclosed. '\n",
      " 'The original pharmaceutical substances are dissolved in a solution or '\n",
      " 'suspended in a suspension, which is sprayed through an atomizing nozzle and '\n",
      " 'frozen in a cold gas phase or liquid nitrogen atomized directly in the '\n",
      " 'spray-freeze chamber or gas jacket at the same time (for cooling purposes). '\n",
      " 'The particles are freeze-dried at roughly atmospheric pressure in a '\n",
      " 'down-stream fluid flow with exit filter thereby to remove moisture entrapped '\n",
      " 'on or inside the frozen particles. The system has applicability for forming '\n",
      " 'other powders.')\n",
      "\n",
      "========================================\n",
      "\n",
      "('A pharmaceutical composition for local application is disclosed, said '\n",
      " 'composition comprising a nucleic acid as a therapeutic agent, an excipient '\n",
      " 'and a pharmaceutically acceptable vehicle therefor, said excipient '\n",
      " 'comprising a liposome. The excipient comprises an amphoteric liposome having '\n",
      " 'an isoelectric point between 4 and 7.4 and said composition is formulated to '\n",
      " 'have a pH in the range 3 to 5. The composition may administered in the form '\n",
      " 'of a colloidal suspension and may be buffered to the lower pH at the time of '\n",
      " 'use by the addition of a suitable acidifying means to a substantially '\n",
      " 'neutral suspension of the nucleic acid and excipient that may be more '\n",
      " 'suitable for long-term storage of the composition. Alternatively, the '\n",
      " 'composition may be lyophilised at the lower pH for subsequent reconstitution '\n",
      " 'just prior to use with a suitable aqueous medium, such for example as '\n",
      " 'substantially unbuffered water or saline.')\n",
      "\n",
      "========================================\n",
      "\n",
      "('The present invention relates to a pharmaceutical composition containing '\n",
      " 'blood cells or haemopoietic cells, e.g. red blood cells (erythrocytes), '\n",
      " 'granulocytes, mononuclear cells (PBMCs) and/or blood platelets, in '\n",
      " 'combination with a pharmaceutically acceptable excipient and/or vehicle, '\n",
      " 'wherein the cells are transfected with at least one mRNA comprising at least '\n",
      " 'one region coding for at least one antigen. The invention further discloses '\n",
      " 'a method of preparing the aforesaid pharmaceutical composition and the use '\n",
      " 'of blood cells transfected in this way for the preparation of drugs or '\n",
      " 'pharmaceutical compositions for immune stimulation against the antigens '\n",
      " 'encoded by the mRNA. The subjects according to the invention are used '\n",
      " 'especially for the therapy and/or prophylaxis of carcinoses or infectious '\n",
      " 'diseases and can also be employed in gene therapy.')\n",
      "\n",
      "========================================\n",
      "\n",
      "('A dry powder formulation for mucosal, intranasal, inhalation or pulmonary '\n",
      " 'delivery which may include one or more siRNAs or dicer-active precursors '\n",
      " 'thereof targeted to a transcript involved in infection by, or replication or '\n",
      " 'production of an influenza virus.')\n",
      "\n",
      "========================================\n",
      "\n",
      "('The present invention relates to a method for immunostimulation in a mammal, '\n",
      " 'which comprises a. administration of at least one mRNA containing a region '\n",
      " 'which codes for at least one antigen of a pathogen or at least one tumour '\n",
      " 'antigen, and b. administration of at least one cytokine, at least one '\n",
      " 'cytokine mRNA, at least one CpG DNA or at least one adjuvant RNA. The '\n",
      " 'invention likewise relates to a product and a kit comprising the mRNA and '\n",
      " 'cytokine or cytokine mRNA or CpG DNA or adjuvant RNA of the invention.')\n",
      "\n",
      "========================================\n",
      "\n",
      "('Methods are provided for administering α1-antitrypsin dry powder pulmonarily '\n",
      " 'to a patient. In these methods, α1-antitrypsin is provided in a dry powder '\n",
      " 'form which is aerosolized and administered to the patient. Apparatus are '\n",
      " 'also provided for carrying out these methods. These methods and apparatus '\n",
      " 'are may generally be used in the treatment of patients suffering from '\n",
      " 'α1-antitrypsin deficiency and the functional derangements of emphysema.')\n",
      "\n",
      "========================================\n",
      "\n",
      "('The invention relates to the use of RNA and an aqueous injection buffer '\n",
      " 'containing a sodium salt, a calcium salt and optionally a potassium salt and '\n",
      " 'optionally lactate, in the preparation of a RNA injection solution for '\n",
      " 'increasing RNA transfer and/or RNA translation into/in a host organism. The '\n",
      " 'invention relates further to a RNA injection solution and to a method for '\n",
      " 'increasing the RNA transfer and/or RNA translation of RNA in vivo and in '\n",
      " 'vitro.')\n",
      "\n",
      "========================================\n",
      "\n",
      "('Spray dried particles having specified aerodynamic characteristics are '\n",
      " 'produced by atomizing a liquid feed and contacting the liquid feed with a '\n",
      " 'drying gas, such as, for example, air or nitrogen. The humidity of the '\n",
      " 'drying gas is controlled to a value, expressed, for instance, as dew point, '\n",
      " 'which is known to produce particles having a specified tap density or '\n",
      " 'aerodynamic diameter. Particles having a volume median geometric diameter '\n",
      " 'greater than about 5 microns and a tap density less than about 0.4 g/cm3 are '\n",
      " 'preferred.')\n",
      "\n",
      "========================================\n",
      "\n",
      "('The present invention generally relates to methods and compositions for the '\n",
      " 'simultaneous delivery of at least one insoluble agent and at least one '\n",
      " 'soluble agent to a cell. In particauar the present invention relates to '\n",
      " 'methods and compositions for the dual delivery of an insoluble agent and a '\n",
      " 'soluble agent to a particular target cell, for example, a leukocyte or '\n",
      " 'endothelial cell. In particular, methods and compositions for simultaneous '\n",
      " 'delivery of a hydrophilic (i.e. soluble) agent and/or a hydrophobic (i.e. '\n",
      " 'insoluble) agent to a leukocyte cell or endothelia cell are disclosed. In '\n",
      " 'one aspect, the present invention provides compositions comprising a '\n",
      " 'targeting moiety that selectively binds one or more integrin ligands on the '\n",
      " 'surface of a leukocyte or endothelial cell; a carrier particle associated '\n",
      " 'with the targeting moiety, wherein the carrier has a lipid phase and an '\n",
      " 'aqueous phase, such as a liposome; an insoluble agent entrapped in the lipid '\n",
      " 'phase of the carrier particle; and/or a soluble agent entrapped in the '\n",
      " 'aqueous phase of the carrier particle.')\n",
      "\n",
      "========================================\n",
      "\n",
      "('The present invention is in the fields of medicine, vaccine and '\n",
      " 'pharmaceutical formulation. The invention provides formulations comprising '\n",
      " 'an angiotensin-virus-like particle conjugate and a stabilizer, wherein said '\n",
      " 'stabilizer comprises a non-reducing disaccharide and a non-ionic surfactant. '\n",
      " 'The lyophilized formulations are stable after a long time of storage at room '\n",
      " 'temperature.')\n",
      "\n",
      "========================================\n",
      "\n",
      "('The present invention is in the fields of medicine, public health, vaccine '\n",
      " 'and drug formulation. The invention provides composition formulations '\n",
      " 'comprising a nicotine-carrier conjugate and a stabilizer, wherein said '\n",
      " 'stabilizer comprises a non-reducing disaccharide and a non-ionic surfactant. '\n",
      " 'The composition formulations are stable after a long time of storage at room '\n",
      " 'temperature.')\n",
      "\n",
      "========================================\n",
      "\n",
      "('The present invention relates to a nucleic acid of the general formula (I): '\n",
      " 'GlXmGn, or (II): ClXmCn, which may be modified by a lipid. The nucleic acid '\n",
      " 'of the invention acts as an immune-stimulating agent inducing the innate '\n",
      " 'immune response. The invention relates further to a pharmaceutical '\n",
      " 'composition (in a first embodiment), each containing an immune-stimulating '\n",
      " 'agent according to the invention in combination with a pharmaceutically '\n",
      " 'active carrier/vehicle (and, optionally, further auxiliary substances, '\n",
      " 'additives and/or further adjuvants). In another embodiment, the inventive '\n",
      " 'nucleic acid is combined with at least one pharmaceutically active '\n",
      " 'component, a pharmaceutically acceptable carrier/vehicle (and, optionally, '\n",
      " 'further auxiliary substances, additives and/or further adjuvants). '\n",
      " 'Accordingly, the present invention is directed to a vaccine, which '\n",
      " 'corresponds to a pharmaceutical composition of the invention (second '\n",
      " 'embodiment), wherein the pharmaceutically active component induces a '\n",
      " 'specific immune response (e.g. an antigen). The present invention relates '\n",
      " 'likewise to the use of a nucleic acid of the invention or a pharmaceutical '\n",
      " 'composition according to the invention for the treatment of infectious '\n",
      " 'diseases, autoimmune diseases, allergies or cancer diseases.')\n",
      "\n",
      "========================================\n",
      "\n",
      "('Carrier nanoparticles comprising a polymer containing a polyol coupled to a '\n",
      " 'polymer containing a boronic acid, configured to present the polymer '\n",
      " 'containing a boronic acid to an environment external to the nanoparticle and '\n",
      " 'related compositions, methods and systems.')\n",
      "\n",
      "========================================\n",
      "\n",
      "('The application describes a method for the preparative purification of RNA, '\n",
      " 'which method is distinguished in that the RNA is purified by means of HPLC '\n",
      " 'using a porous reversed phase as the stationary phase. The use of the porous '\n",
      " 'reversed phase in this HPLC method is also described.')\n",
      "\n",
      "========================================\n",
      "\n",
      "('The present invention provides superior compositions and methods for the '\n",
      " 'delivery of therapeutic agents to cells. In particular, these include novel '\n",
      " 'lipids and nucleic acid-lipid particles that provide efficient encapsulation '\n",
      " 'of nucleic acids and efficient delivery of the encapsulated nucleic acid to '\n",
      " 'cells in vivo. The compositions of the present invention are highly potent, '\n",
      " 'thereby allowing effective knock-down of specific target proteins at '\n",
      " 'relatively low doses. In addition, the compositions and methods of the '\n",
      " 'present invention are less toxic and provide a greater therapeutic index '\n",
      " 'compared to compositions and methods previously known in the art.')\n",
      "\n",
      "========================================\n",
      "\n",
      "('The present invention provides lipids that are advantageously used in lipid '\n",
      " 'particles for the in vivo delivery of therapeutic agents to cells. In '\n",
      " 'particular, the invention formula (I) provides lipids having the following '\n",
      " 'structure XXXIII wherein: R1 and R2 are each independently for each '\n",
      " 'occurrence optionally substituted C10-C30 alkyl, optionally substituted '\n",
      " 'C10-C30 alkenyl, optionally substituted C10-C30 alkynyl, optionally '\n",
      " 'substituted C10-C30 acyl, or -linker-ligand; R3 is H, optionally substituted '\n",
      " 'C1- C10 alkyl, optionally substituted C2-C10 alkenyl, optionally substituted '\n",
      " 'C2-C10 alkynyl, alky lhetro cycle, alkylphosphate, alkylphosphorothioate, '\n",
      " 'alkylphosphorodithioate, alkylphosphonates, alkylamines, hydroxyalkyls, '\n",
      " 'ω-aminoalkyls, ω - (substituted)aminoalkyls, ω -phosphoalkyls, ω '\n",
      " '-thiophosphoalkyls, optionally substituted polyethylene glycol (PEG, mw '\n",
      " '100-40K), optionally substituted mPEG (mw 120-40K), heteroaryl, heterocycle, '\n",
      " 'or linker-ligand; and E is C(O)O or OC(O).')\n",
      "\n",
      "========================================\n",
      "\n",
      "('The present invention provides amphipathic lipid compounds comprising a '\n",
      " 'hydrophilic, catonic, pH-sensitive moiety, the positive charge of which '\n",
      " 'moiety increases as pH decreases over the pH range of 8.0 to 4.5. Vesicular '\n",
      " 'delivery systems comprising such amphipathic compounds and the use of those '\n",
      " 'systems for delivering biologically active substances to cells are also '\n",
      " 'provided.')\n",
      "\n",
      "========================================\n",
      "\n",
      "('Aminoalcohol lipidoids are prepared by reacting an amine with an '\n",
      " 'epoxide-terminated compound are described. Methods of preparing aminoalcohol '\n",
      " 'lipidoids from commercially available starting materials are also provided. '\n",
      " 'Aminoalcohol lipidoids may be prepared from racemic or stereochemically pure '\n",
      " 'epoxides. Aminoalcohol lipidoids or salts forms thereof are preferably '\n",
      " 'biodegradable and biocompatible and may be used in a variety of drug '\n",
      " 'delivery systems. Given the amino moiety of these aminoalcohol lipidoid '\n",
      " 'compounds, they are particularly suited for the delivery of polynucleotides. '\n",
      " 'Complexes, micelles, liposomes or particles containing the inventive '\n",
      " 'lipidoids and polynucleotide have been prepared. The inventive lipidoids may '\n",
      " 'also be used in preparing microparticles for drug delivery. They are '\n",
      " 'particularly useful in delivering labile agents given their ability to '\n",
      " 'buffer the pH of their surroundings.')\n",
      "\n",
      "========================================\n",
      "\n",
      "('Compounds of Formula (I) that inhibit Btk are described herein. '\n",
      " 'Pharmaceutical compositions comprising at least one compound of Formula (I), '\n",
      " 'together with at least one pharmaceutically acceptable vehicle chosen from '\n",
      " 'carriers, adjuvants, and excipients, are described. Methods of treating '\n",
      " 'patients suffering from certain diseases responsive to inhibition of Btk '\n",
      " 'activity and / or B-cell activity are described. Methods for determining the '\n",
      " 'presence of Btk in a sample are described.')\n",
      "\n",
      "========================================\n",
      "\n",
      "('The present invention provides compositions comprising cationic lipids, '\n",
      " 'liposomes and nucleic acid-lipid particles comprising the cationic lipids, '\n",
      " 'and methods of using such compositions, liposomes, and nucleic acid-lipid '\n",
      " 'particles.')\n",
      "\n",
      "========================================\n",
      "\n",
      "('The present application describes an antibody-coding, non-modified or '\n",
      " 'modified RNA and the use thereof for expression of this antibody, for the '\n",
      " 'preparation of a pharmaceutical composition, in particular a passive '\n",
      " 'vaccine, for treatment of tumours and cancer diseases, cardiovascular '\n",
      " 'diseases, infectious diseases, auto-immune diseases, virus diseases and '\n",
      " 'monogenetic diseases, e.g. also in gene therapy. The present invention '\n",
      " 'furthermore describes an in vitro transcription method, in vitro methods for '\n",
      " 'expression of this antibody using the RNA according to the invention and an '\n",
      " 'in vivo method.')\n",
      "\n",
      "========================================\n",
      "\n",
      "('The present invention relates to a complexed RNA, comprising at least one '\n",
      " 'RNA complexed with one or more oligopeptides, wherein the oligopeptide, '\n",
      " 'which has the function of cell-penetrating peptide (CPP), has a length of 8 '\n",
      " 'to 15 amino acids and has the empirical formula (Arg)l; (Lys)m; (His)n; '\n",
      " '(Orn)o; (Xaa)x with the majority of residues being selected from Arg, Lys, '\n",
      " 'His, Orn. The invention further relates to a method for transfecting a cell '\n",
      " 'or an organism, thereby applying the inventive complexed RNA. Additionally, '\n",
      " 'pharmaceutical compositions and kits comprising the inventive complexed RNA, '\n",
      " 'as well as the use of the inventive complexed RNA for transfecting a cell, '\n",
      " 'tissue or an organism and/or for modulating, preferably inducing or '\n",
      " 'enhancing, an immune response are disclosed herein.')\n",
      "\n",
      "========================================\n",
      "\n",
      "('The present invention relates to an active (immunostimulatory) composition '\n",
      " 'comprising at least one RNA, preferably a mRNA, encoding at least two '\n",
      " '(preferably different) antigens capable of eliciting an (adaptive) immune '\n",
      " 'response in a mammal. The invention furthermore relates to a vaccine '\n",
      " 'comprising said active (immunostimulatory) composition, and to the use of '\n",
      " 'said active (immunostimulatory) composition (for the preparation of a '\n",
      " 'vaccine) and/or of the vaccine for eliciting an (adaptive) immune response '\n",
      " 'for the treatment of lung cancer, particularly of non-small cell lung '\n",
      " 'cancers (NSCLC), preferably selected from the three main sub-types squamous '\n",
      " 'cell lung carcinoma, adenocarcinoma and large cell lung carcinoma, or of '\n",
      " 'disorders related thereto. Finally, the invention relates to kits, '\n",
      " 'particularly to kits of parts, containing the active (immunostimulatory) '\n",
      " 'composition and/or the vaccine.')\n",
      "\n",
      "========================================\n",
      "\n",
      "('The present invention relates to an active (immunostimulatory) composition '\n",
      " 'comprising at least one RNA, preferably an mRNA, encoding at least two '\n",
      " '(preferably different) antigens capable of eliciting an (adaptive) immune '\n",
      " 'response in a mammal wherein the antigens are selected from the group '\n",
      " 'consisting of PSA (Prostate-Specific Antigen), PSMA (Prostate-Specific '\n",
      " 'Membrane Antigen), PSCA (Prostate Stem Cell Antigen), and STEAP (Six '\n",
      " 'Transmembrane Epithelial Antigen of the Prostate). The invention furthermore '\n",
      " 'relates to a vaccine comprising said active (immunostimulatory) composition, '\n",
      " 'and to the use of said active (immunostimulatory) composition (for the '\n",
      " 'preparation of a vaccine) and/or of the vaccine for eliciting an (adaptive) '\n",
      " 'immune response for the treatment of prostate cancer (PCa), preferably of '\n",
      " 'neoadjuvant and/or hormone-refractory prostate cancers, and diseases or '\n",
      " 'disorders related thereto. Finally, the invention relates to kits, '\n",
      " 'particularly to kits of parts, containing the active (immunostimulatory) '\n",
      " 'composition and/or the vaccine.')\n",
      "\n",
      "========================================\n",
      "\n",
      "('The invention relates to a polyribonucleotide with a sequence that codes a '\n",
      " 'protein or protein fragment, wherein the polyribonucleotide comprises a '\n",
      " 'combination of unmodified and modified nucleotides, wherein 5 to 50% of the '\n",
      " 'uridine nucleotides and 5 to 50% of the cytidin nucleotides are modified '\n",
      " 'uridine nucleotides or modified cytidin nucleotides.')\n",
      "\n",
      "========================================\n",
      "\n",
      "('The present invention is directed to an inventive polymeric carrier molecule '\n",
      " 'according to generic formula (I) and variations thereof, which allows for '\n",
      " 'efficient transfection of nucleic acids into cells in vivo and in vitro, a '\n",
      " 'polymeric carrier cargo complex formed by a nucleic acid and the inventive '\n",
      " 'polymeric carrier molecule, but also methods of preparation of this '\n",
      " 'inventive polymeric carrier molecule and of the inventive polymeric carrier '\n",
      " 'complex. The present invention also provides methods of application and use '\n",
      " 'of this inventive polymeric carrier and the inventive polymeric carrier '\n",
      " 'cargo complex as a medicament, for the treatment of various diseases, and in '\n",
      " 'the preparation of a pharmaceutical composition for the treatment such '\n",
      " 'diseases.')\n",
      "\n",
      "========================================\n",
      "\n",
      "('The present invention is directed to the lyophilization of nucleic acids in '\n",
      " 'lactate-containing solutions or formulations. The present invention is '\n",
      " 'particularly suitable for enhancing and improving storage and shipping '\n",
      " 'capabilities of nucleic acids for multiple purposes. The present invention '\n",
      " 'is furthermore directed to methods of lyophilization suitable to prepare '\n",
      " 'such inventive lyophilized nucleic acids, to the use of such lyophilized '\n",
      " 'nucleic acids in the preparation of pharmaceutical compositions, to first '\n",
      " 'and second medical indications using such lyophilized nucleic acids and to '\n",
      " 'kits, particularly to kit of parts, comprising such lyophilized nucleic '\n",
      " 'acids.')\n",
      "\n",
      "========================================\n",
      "\n",
      "('Compositions and methods are provided for the administration of particulates '\n",
      " 'comprising at least one bioactive agent which, in selected embodiments, may '\n",
      " 'comprise an immunoactive agent. In this respect, the invention provides for '\n",
      " 'both topical and systemic delivery of the bioactive agent using, for '\n",
      " 'example, the respiratory, gastrointestinal or urogenital tracts. The '\n",
      " 'particulates may be in the form of dry powders or combined with a nonaqueous '\n",
      " 'suspension medium to provide stabilized dispersions. In preferred '\n",
      " 'embodiments, the disclosed compositions will be used in conjunction with '\n",
      " 'inhalation devices such as metered dose inhalers, dry powder inhalers, '\n",
      " 'atomizers or nebulizers for targeted delivery of the agent to mucosal '\n",
      " 'surfaces.')\n",
      "\n",
      "========================================\n",
      "\n",
      "('A method for delivering a nucleic acid to a cell can include exposing sample '\n",
      " 'cells to a composition which includes charged lipids.')\n",
      "\n",
      "========================================\n",
      "\n",
      "('The present invention is directed to (the use of) a solution containing at '\n",
      " 'least one nucleic acid (sequence) and free mannose for lyophilization, '\n",
      " 'transfection and/or injection, particularly of RNA and mRNA. The inventive '\n",
      " 'solution exhibits a positive effect on stabilization of the nucleic acid '\n",
      " '(sequence) during lyophilization and storage but also leads to a '\n",
      " 'considerable increase of the transfection efficiency of a nucleic acid. It '\n",
      " 'thus also increases in vivo expression of a protein encoded by such a '\n",
      " 'nucleic acid upon increased transfection rate. The present invention is '\n",
      " 'furthermore directed to a method of lyophilization using the '\n",
      " 'mannose-containing solution, to pharmaceutical compositions, vaccines, kits, '\n",
      " 'first and second medical uses applying such a mannose-containing solution '\n",
      " 'and/or a nucleic acid (sequence) lyophilized or resuspended with such a '\n",
      " 'solution.')\n",
      "\n",
      "========================================\n",
      "\n",
      "('Disclosed are methods for preparing dried (preferably lyophilized) '\n",
      " 'preparations comprising a population of alphaviruses or alphavirus replicon '\n",
      " 'particles, a sugar or polyol, a surfactant and a salt and preparations made '\n",
      " 'by these methods, both in the dried form but also as liquids prior to drying '\n",
      " 'or after reconstituting dried preparations. These preparations may further '\n",
      " 'comprise a plasticizer and/or a bulking agent. These preparations are '\n",
      " 'readily reconstituted, with little or no loss in infectivity of the viruses '\n",
      " 'or replicon particles.')\n",
      "\n",
      "========================================\n",
      "\n",
      "('This invention provides methods and compositions to preserve bioactive '\n",
      " 'materials, such as peptides, nucleic acids, viruses, bacteria, cells, or '\n",
      " 'liposomes, in freeze dried particles suitable for intranasal administration. '\n",
      " 'Methods provide spray freeze drying of formulations to form stable freeze '\n",
      " 'dried particles for intranasal administration.')\n",
      "\n",
      "========================================\n",
      "\n",
      "('The present invention relates to an immunostimulatory composition comprising '\n",
      " 'a) an adjuvant component, comprising or consisting of at least one (m)RNA, '\n",
      " 'complexed with a cationic or polycationic compound, and b) at least one free '\n",
      " 'mRNA, encoding at least one therapeutically active protein, antigen, '\n",
      " 'allergen and/or antibody, wherein the immunostimulatory composition is '\n",
      " 'capable to elicit or enhance an innate and optionally an adaptive immune '\n",
      " 'response in a mammal. The inventive immunostimulatory composition may be a '\n",
      " 'pharmaceutical composition or a vaccine. The invention furthermore relates '\n",
      " 'to a method of preparation of the inventive immunostimulatory composition. '\n",
      " 'The invention also relates to the use of the inventive immunostimulatory '\n",
      " 'composition or its components (for the preparation of a pharmaceutical '\n",
      " 'composition or a vaccine) for the treatment of various diseases. Finally, '\n",
      " 'the invention relates to kits containing the inventive immunostimulatory '\n",
      " 'composition, its components and/or the pharmaceutical composition or '\n",
      " 'vaccine.')\n",
      "\n",
      "========================================\n",
      "\n",
      "('The present invention relates to nucleic acids of the general formula (I): '\n",
      " '(NuGlXmGnNv)a and derivatives thereof as an immunostimulating agent/adjuvant '\n",
      " 'and to compositions containing same, optionally comprising an additional '\n",
      " 'adjuvant. The present invention furthermore relates to a pharmaceutical '\n",
      " 'composition or to a vaccine, each containing nucleic acids of formula (I) '\n",
      " 'above and/or derivatives thereof as an immunostimulating agent, and '\n",
      " 'optionally at least one additional pharmaceutically active component, e.g. '\n",
      " 'an antigenic agent. The present invention relates likewise to the use of the '\n",
      " 'pharmaceutical composition or of the vaccine for the treatment of cancer '\n",
      " 'diseases, infectious diseases, allergies and autoimmune diseases etc. '\n",
      " 'Likewise, the present invention includes the use of nucleic acids of the '\n",
      " 'general formula (I): (NuGlXmGnNv)a and/or derivatives thereof for the '\n",
      " 'preparation of a pharmaceutical composition for the treatment of such '\n",
      " 'diseases.')\n",
      "\n",
      "========================================\n",
      "\n",
      "('Disclosed herein are novel compounds, pharmaceutical compositions comprising '\n",
      " 'such compounds and related methods of their use. The compounds described '\n",
      " 'herein are useful, e.g., as liposomal delivery vehicles to facilitate the '\n",
      " 'delivery of encapsulated polynucleotides to target cells and subsequent '\n",
      " 'iransfection of said target cells, and in certain embodiments are '\n",
      " 'characterized as having one or more properties that afford such compounds '\n",
      " 'advantages relative to other similarly classified lipids.')\n",
      "\n",
      "========================================\n",
      "\n",
      "('The present application describes a coding nucleic acid sequence, '\n",
      " 'particularly a messenger RNA (mRNA), comprising or coding for a histone '\n",
      " 'stem-loop and a poly(A) sequence or a polyadenylation signal and the use '\n",
      " 'thereof for increasing the expression of an encoded protein. It also '\n",
      " 'discloses its use for the preparation of a pharmaceutical composition, '\n",
      " 'especially a vaccine e.g. for the use in the treatment of tumours and cancer '\n",
      " 'diseases, cardiovascular diseases, infectious diseases, autoimmune diseases '\n",
      " 'or genetic diseases, or in gene therapy. The present invention further '\n",
      " 'describes an in vitro transcription method, in vitro methods for increasing '\n",
      " 'the expression of a protein using the nucleic acid comprising or coding for '\n",
      " 'a histone stem-loop and a poly(A) sequence or a polyadenylation signal and '\n",
      " 'an ex vivo and in vivo method.')\n",
      "\n",
      "========================================\n",
      "\n",
      "('The present invention is directed to a polymeric carrier cargo complex, '\n",
      " 'comprising as a cargo at least one nucleic acid (molecule) and '\n",
      " 'disulfide-crosslinked cationic components as a (preferably non-toxic and '\n",
      " 'non-immunogenic) polymeric carrier. The inventive polymeric carrier cargo '\n",
      " 'complex allows for both efficient transfection of nucleic acids into cells '\n",
      " 'in vivo and in vitro and/or for induction of an (innate and/or adaptive) '\n",
      " 'immune response, preferably dependent on the nucleic acid to be transported '\n",
      " 'as a cargo. The present invention also provides, pharmaceutical '\n",
      " 'compositions, particularly vaccines and adjuvants, comprising the inventive '\n",
      " 'polymeric carrier cargo complex and optionally an antigen, as well as the '\n",
      " 'use of such the inventive polymeric carrier cargo complex and optionally an '\n",
      " 'antigen for transfecting a cell, a tissue or an organism, for '\n",
      " '(gene-)therapeutic purposes as disclosed herein, and/or as an '\n",
      " 'immunostimulating agent or adjuvant, e.g. for eliciting an immune response '\n",
      " 'for the treatment or prophylaxis of diseases as mentioned above. Finally, '\n",
      " 'the invention relates to kits containing the inventive polymeric carrier '\n",
      " 'cargo complex and/or the inventive pharmaceutical composition, adjuvant or '\n",
      " 'vaccine in one or more parts of the kit.')\n",
      "\n",
      "========================================\n",
      "\n",
      "('The present invention is directed to an inventive composition or vaccine '\n",
      " 'composition comprising a) an adjuvant component comprising or consisting of '\n",
      " 'at least one immunostimulatory nucleic acid sequence, complexed with a '\n",
      " 'complexing agent; b) an antigen, preferably a protein or peptide antigen '\n",
      " 'and/or a nucleic acid sequence encoding said antigen; and c) a carrier '\n",
      " 'molecule for combined packaging the adjuvant component and the antigen. The '\n",
      " 'present invention is also directed to the first medical use of such an '\n",
      " 'inventive composition or vaccine composition and to the second medical use '\n",
      " 'of such an inventive composition or vaccine composition or components '\n",
      " 'thereof for the treatment of diseases, such as infectious or cancer or '\n",
      " 'tumour diseases as defined herein. The present invention furthermore '\n",
      " 'discloses kits comprising such a composition or vaccine composition.')\n",
      "\n",
      "========================================\n",
      "\n",
      "('The invention provides a method for the transfer of RNA,\\n'\n",
      " 'especially mRNA, into cells and into organisms. This method\\n'\n",
      " 'is especially suited for applications in the field of gene\\n'\n",
      " 'therapy. The RNA is transferred in the form of a complex\\n'\n",
      " 'between at least one RNA and at least one cationic, especially\\n'\n",
      " 'polycationic, peptide or protein. Preferably protamine,\\n'\n",
      " 'poly-L-lysine and/or histone is used as cationic peptide or\\n'\n",
      " 'protein.')\n",
      "\n",
      "========================================\n",
      "\n",
      "('The present invention relates to a vaccine/inhibitor combination comprising '\n",
      " 'as a vaccine at least one antigen and as an inhibitor at least one inhibitor '\n",
      " 'of the major histocompatibility complex (MHC) class I restricted antigen '\n",
      " 'presentation. The present invention furthermore relates to a method of '\n",
      " 'vaccination of a mammal using the inventive vaccine/inhibitor combination. '\n",
      " 'The present invention also provides kit of parts comprising the inventive '\n",
      " 'vaccine/inhibitor combination, preferably in different parts of the kit, '\n",
      " 'e.g. for prior, concurrent or subsequent administration of the different '\n",
      " 'parts. Additionally the invention relates to a pharmaceutical composition '\n",
      " 'comprising the inventive vaccine/inhibitor combination to further improve '\n",
      " 'the immune response against tumour cells and infected cells having lost the '\n",
      " 'capability of MHC class I restricted antigen presentation.')\n",
      "\n",
      "========================================\n",
      "\n",
      "('The present invention relates to vaccines comprising at least one mRNA '\n",
      " 'encoding at least one antigen for use in the treatment of a disease in an '\n",
      " 'elderly patient preferably exhibiting an age of at least 50 years, more '\n",
      " 'preferably of at least 55 years, 60 years, 65 years, 70 years, or older, '\n",
      " 'wherein the treatment comprises vaccination of the patient and eliciting an '\n",
      " 'immune response in said patient. The present invention is furthermore '\n",
      " 'directed to kits and kits of parts comprising such a vaccine and/or its '\n",
      " 'components and to methods applying such a vaccine or kit.')\n",
      "\n",
      "========================================\n",
      "\n",
      "('Compositions comprising mRNA fonnulated for pulmonary administration and '\n",
      " 'related methods for delivery of the mRNA and/or encoded protein to a '\n",
      " 'non-lung cell or tissue. The compositions and methods may be used to prevent '\n",
      " 'or ameliorate the symptoms of diseases associated with the mRNA encoded '\n",
      " 'protein.')\n",
      "\n",
      "========================================\n",
      "\n",
      "('The present invention relates to vaccines comprising at least one mRNA '\n",
      " 'encoding at least one antigen for use in the treatment of a disease in '\n",
      " 'newborns and/or infants, preferably exhibiting an age of not more than 2 '\n",
      " 'years, preferably of not more than 1 year, more preferably of not more than '\n",
      " '9 months or even 6 months, wherein the treatment comprises vaccination of '\n",
      " 'the newborn or infant and eliciting an immune response in said newborn or '\n",
      " 'infant. The present invention is furthermore directed to kits and kits of '\n",
      " 'parts comprising such a vaccine and/or its components and to methods '\n",
      " 'applying such a vaccine or kit.')\n",
      "\n",
      "========================================\n",
      "\n",
      "('The invention provides a new production process for large-scale synthesis of '\n",
      " 'long-chain RNA drugs. The process is characterized by specifically including '\n",
      " 'the steps of: DNA transcription template design; template preparation and '\n",
      " 'purification; in-vitro transcription; and product purification, purity '\n",
      " 'detection and the like. The production process provided by the invention is '\n",
      " 'especially suitable for synthesis of long-chain RNA drugs with a stable '\n",
      " 'secondary structure. With the characteristics of simple operation and low '\n",
      " 'cost, the process provided by the invention meets the requirements of '\n",
      " 'large-scale production, and the produced long-chain RNA drugs can be used '\n",
      " \"for cell experiments, animal experiments and other preclinical RNA drugs' \"\n",
      " 'functional study.')\n",
      "\n",
      "========================================\n",
      "\n",
      "('The present invention relates to a polyelectrolyte complex composition '\n",
      " 'comprising a polymer, a nucleic acid molecule, a lyoprotectant, and a '\n",
      " 'buffer. The polyelectrolyte complex composition preserving the biological '\n",
      " 'activities of the polyelectrolyte complex following freeze-drying and '\n",
      " 'rehydration.')\n",
      "\n",
      "========================================\n",
      "\n",
      "('The present invention is directed to a pharmaceutical composition including '\n",
      " '(eg for use as an adjuvant) a polymeric carrier cargo complex, comprising as '\n",
      " 'a carrier a polymeric carrier formed by disulfide-crosslinked cationic '\n",
      " 'components and as a cargo at least one nucleic acid (molecule) and at least '\n",
      " 'one antigen associated with a tumour or cancer disease selected from; an '\n",
      " 'idiotype immunoglobulin (e.g. an idiotype antibody or an idiotype B cell '\n",
      " 'receptor); or at least one idiotype T cell receptor, or in each case a '\n",
      " 'fragment, variant and/or derivative thereof. The inventive pharmaceutical '\n",
      " 'composition allows for efficient induction of an adaptive immune response '\n",
      " 'directed against the idiotype immunoglobulin or T cell receptor, '\n",
      " 'particularly of a Th1-shiftet immune response. The present invention '\n",
      " 'furthermore provides kits or kits of parts comprising the components of the '\n",
      " 'inventive pharmaceutical composition, as well as the use of the inventive '\n",
      " 'pharmaceutical composition or the inventive kit as a vaccine, particularly '\n",
      " 'in the therapy of a tumour or cancer disease such as lymphoma, particularly '\n",
      " 'B cell or T cell lymphoma.')\n",
      "\n",
      "========================================\n",
      "\n",
      "('The invention relates to an artificial nucleic acid molecule comprising at '\n",
      " 'least one 5′UTR element which is derived from a TOP gene, at least one open '\n",
      " 'reading frame and optionally at least one 3′UTR element comprising a nucleic '\n",
      " 'acid sequence which is preferably derived from the 3′UTR of a gene providing '\n",
      " 'a stable mRNA, such as an albumin gene, or from a variant of the 3′UTR of a '\n",
      " 'gene providing a stable mRNA. The invention further relates to the use of '\n",
      " 'such an artificial nucleic acid molecule in gene therapy and/or genetic '\n",
      " 'vaccination.')\n",
      "\n",
      "========================================\n",
      "\n",
      "('The present invention relates to a nucleic acid sequence, comprising or '\n",
      " 'coding for a coding region, encoding at least one peptide or protein '\n",
      " 'comprising a therapeutic protein or a fragment, variant or derivative '\n",
      " 'thereof, at least one histone stem-loop and a poly(A) sequence or a '\n",
      " 'polyadenylation signal. Furthermore the present invention provides the use '\n",
      " 'of the nucleic acid for increasing the expression of said encoded peptide or '\n",
      " 'protein, particularly for the use in gene therapy. It also discloses its use '\n",
      " 'for the preparation of a pharmaceutical composition, e.g. for use in gene '\n",
      " 'therapy, particularly in the treatment of diseases which are in need of a '\n",
      " 'treatment with a therapeutic peptide or protein, preferably as defined '\n",
      " 'herein. The present invention further describes a method for increasing the '\n",
      " 'expression of a peptide or protein comprising a therapeutic protein or a '\n",
      " 'fragment, variant or derivative thereof, using the nucleic acid comprising '\n",
      " 'or coding for a histone stem-loop and a poly(A) sequence or a '\n",
      " 'polyadenylation signal.')\n",
      "\n",
      "========================================\n",
      "\n",
      "('The present invention relates to a nucleic acid sequence, comprising or '\n",
      " 'coding for a coding region, encoding at least one peptide or protein '\n",
      " 'comprising a pathogenic antigen or a fragment, variant or derivative '\n",
      " 'thereof, at least one histone stem-loop and a poly(A) sequence or a '\n",
      " 'polyadenylation signal. Furthermore the present invention provides the use '\n",
      " 'of the nucleic acid for increasing the expression of said encoded peptide or '\n",
      " 'protein. It also discloses its use for the preparation of a pharmaceutical '\n",
      " 'composition, especially a vaccine, e.g. for use in the treatment of '\n",
      " 'infectious diseases. The present invention further describes a method for '\n",
      " 'increasing the expression of a peptide or protein comprising a pathogenic '\n",
      " 'antigen or a fragment, variant or derivative thereof, using the nucleic acid '\n",
      " 'comprising or coding for a histone stem-loop and a poly(A) sequence or a '\n",
      " 'polyadenylation signal.')\n",
      "\n",
      "========================================\n",
      "\n",
      "('This invention relates to formulations comprising biological samples '\n",
      " 'preserved as dry glassy powders and hydrophobic carriers, the formulations '\n",
      " 'being adapted for the long-term storage and delivery of the bioactive '\n",
      " 'materials, in particular viral and bacterial vaccines, vectors and cells, at '\n",
      " 'ambient or higher temperatures, and to methods for preparing these '\n",
      " 'formulations.')\n",
      "\n",
      "========================================\n",
      "\n",
      "('The present invention is directed to a pharmaceutical composition including '\n",
      " '(e.g., for use as an adjuvant) a (negatively charged) nucleic acid '\n",
      " 'comprising complex comprising as a carrier cationic or polycationic '\n",
      " 'compounds (e.g. peptides, proteins or polymers) and as a cargo at least one '\n",
      " 'nucleic acid (molecule) and at least one antigen that is selected from an '\n",
      " 'antigen from a pathogen associated with infectious disease; an antigen '\n",
      " 'associated with allergy or allergic disease; an antigen associated with '\n",
      " 'autoimmune disease; or an antigen associated with a cancer or tumour '\n",
      " 'disease, or in each case a fragment, variant and/or derivative of said '\n",
      " 'antigen. The pharmaceutical composition allows for efficient induction of an '\n",
      " 'adaptive immune response directed against said antigen. The present '\n",
      " 'invention furthermore provides kits, as well as the use of the '\n",
      " 'pharmaceutical composition or the kit as a vaccine, particularly in the '\n",
      " 'treatment of infectious diseases, allergies, autoimmune diseases and tumour '\n",
      " 'or cancer diseases.')\n",
      "\n",
      "========================================\n",
      "\n",
      "('The present invention is directed to a pharmaceutical composition including '\n",
      " '(e.g. for use as an adjuvant) a polymeric carrier cargo complex, comprising '\n",
      " 'as a carrier a polymeric carrier formed by disulfide-crosslinked cationic '\n",
      " 'components; and as a cargo at least one nucleic acid molecule, and at least '\n",
      " 'one antigen that is selected from an antigen from a pathogen associated with '\n",
      " 'infectious disease; an antigen associated with allergy or allergic disease; '\n",
      " 'an antigen associated with autoimmune disease; or an antigen associated with '\n",
      " 'a cancer or tumour disease, or in each case a fragment, variant and/or '\n",
      " 'derivative of said antigen. The pharmaceutical composition allows for '\n",
      " 'efficient induction of an adaptive immune response directed against said '\n",
      " 'antigen. The present invention furthermore provides kits, as well as the use '\n",
      " 'of the pharmaceutical composition or the kit as a vaccine, particularly in '\n",
      " 'the treatment of infectious diseases, allergies, autoimmune diseases and '\n",
      " 'tumour or cancer diseases.')\n",
      "\n",
      "========================================\n",
      "\n",
      "('The invention related to dry powders that contain a therapeutic agent. The '\n",
      " 'dry powders have characteristics, e.g., they are processable and/or dense in '\n",
      " 'therapeutic agent that provide advantages for formulating and delivering '\n",
      " 'therapeutic agents to patients.')\n",
      "\n",
      "========================================\n",
      "\n",
      "('The present invention relates to a nucleic acid sequence, comprising or '\n",
      " 'coding for a coding region, encoding at least one peptide or protein '\n",
      " 'comprising an allergenic antigen or an autoimmune self-antigen or a '\n",
      " 'fragment, variant or derivative thereof, at least one histone stem-loop and '\n",
      " 'a poly(A) sequence or a polyadenylation signal. Furthermore the present '\n",
      " 'invention provides the use of the nucleic acid for increasing the expression '\n",
      " 'of said encoded peptide or protein. It also discloses its use for the '\n",
      " 'preparation of a pharmaceutical composition, especially a vaccine, e.g. for '\n",
      " 'use in the treatment of allergies or autoimmune diseases. The present '\n",
      " 'invention further describes a method for increasing the expression of a '\n",
      " 'peptide or protein comprising an allergenic antigen or an autoimmune '\n",
      " 'self-antigen or a fragment, variant or derivative thereof, using the nucleic '\n",
      " 'acid comprising or coding for a histone stem-loop and a poly(A) sequence or '\n",
      " 'a polyadenylation signal.')\n",
      "\n",
      "========================================\n",
      "\n",
      "('The invention relates to an artificial nucleic acid molecule comprising at '\n",
      " 'least one open reading frame and at least one 3′UTR element comprising a '\n",
      " 'nucleic acid sequence which is derived from the 3′UTR of an albumin gene or '\n",
      " 'from a variant of the 3′UTR of an albumin gene. The invention further '\n",
      " 'relates to the use of such an artificial nucleic acid molecule in gene '\n",
      " 'therapy and/or genetic vaccination. Furthermore, the invention relates to '\n",
      " 'the use of a 3′UTR element comprising a nucleic acid sequence which is '\n",
      " 'derived from the 3′UTR of an albumin gene or from a variant of the 3′UTR of '\n",
      " 'an albumin gene for the stabilization and/or prolongation of protein '\n",
      " 'expression from a nucleic acid sequence comprising such 3′UTR element.')\n",
      "\n",
      "========================================\n",
      "\n",
      "('The invention relates to an artificial nucleic acid molecule comprising at '\n",
      " 'least one 5′UTR element which is derived from a TOP gene, at least one open '\n",
      " 'reading frame, and preferably at least one histone stem-loop. Optionally the '\n",
      " 'artificial nucleic acid molecule may further comprise, e.g. a '\n",
      " 'poly(A)sequence, a poyladenylation signal, and/or a 3′UTR. The invention '\n",
      " 'further relates to the use of such an artificial nucleic acid molecule in '\n",
      " 'gene therapy and/or genetic vaccination.')\n",
      "\n",
      "========================================\n",
      "\n",
      "('The present invention relates to nanoparticles comprising nucleic acids '\n",
      " 'coated with a (biodegradable) polymer for reversible immobilization and/or '\n",
      " 'controlled release of the nucleic acid comprising nanoparticles. '\n",
      " 'Furthermore, the present invention is directed to medical or diagnostic '\n",
      " 'devices, particularly stents and implants coated by a (biodegradable) '\n",
      " 'polymer with the nucleic acid comprising nanoparticles for reversible '\n",
      " 'immobilization and/or controlled release. Furthermore, the present invention '\n",
      " 'is directed to the use of these nanoparticles coated with a (biodegradable) '\n",
      " 'polymer and to the use of medical devices and implants coated by the '\n",
      " '(biodegradable) polymer with these nucleic acid comprising nanoparticles in '\n",
      " 'the prophylactic or therapeutic treatment of diseases, particularly in the '\n",
      " 'prevention or treatment of restenosis, calicification, foreign body '\n",
      " 'reaction, or inflammation. Additionally, the present invention is directed '\n",
      " 'to a method of preparing these nucleic acid comprising nanoparticles coated '\n",
      " 'with a (biodegradable) polymer and to a method for coating nucleic acid '\n",
      " 'comprising nanoparticles by a (biodegradable) polymer on medical or '\n",
      " 'diagnostic devices.')\n",
      "\n",
      "========================================\n",
      "\n",
      "('The present invention relates to a nucleic acid sequence, comprising or '\n",
      " 'coding for a coding region, encoding at least one peptide or protein '\n",
      " 'comprising a tumour antigen or a fragment, variant or derivative thereof, at '\n",
      " 'least one histone stem-loop and a poly(A) sequence or a polyadenylation '\n",
      " 'signal. Furthermore the present invention provides the use of the nucleic '\n",
      " 'acid for increasing the expression of said encoded peptide or protein. It '\n",
      " 'also discloses its use for the preparation of a pharmaceutical composition, '\n",
      " 'especially a vaccine, e.g. for use in the treatment of cancer or tumour '\n",
      " 'diseases. The present invention further describes a method for increasing '\n",
      " 'the expression of a peptide or protein comprising a tumour antigen or a '\n",
      " 'fragment, variant or derivative thereof, using the nucleic acid comprising '\n",
      " 'or coding for a histone stem-loop and a poly(A) sequence or a '\n",
      " 'polyadenylation signal.')\n",
      "\n",
      "========================================\n",
      "\n",
      "('The present invention relates to a vaccine/inhibitor combination comprising '\n",
      " 'an RNA vaccine comprising at least one RNA comprising at least one open '\n",
      " 'reading frame (ORF) coding for at least one antigen and a composition '\n",
      " 'comprising at least one PD-1 pathway inhibitor, preferably directed against '\n",
      " 'PD-1 receptor or its ligands PD-L1 and PD-L2. The present invention '\n",
      " 'furthermore relates to a pharmaceutical composition and a kit of parts '\n",
      " 'comprising the components of such a vaccine/inhibitor combination. '\n",
      " 'Additionally the present invention relates to medical use of such a '\n",
      " 'vaccine/inhibitor combination, the pharmaceutical composition and the kit of '\n",
      " 'parts comprising such a vaccine/inhibitor combination, particularly for the '\n",
      " 'prevention or treatment of tumor or cancer diseases or infectious diseases. '\n",
      " 'Furthermore, the present invention relates to the use of an RNA vaccine in '\n",
      " 'therapy in combination with a PD-1 pathway inhibitor and to the use of a '\n",
      " 'PD-1 pathway inhibitor in therapy in combination with an RNA vaccine.')\n",
      "\n",
      "========================================\n",
      "\n",
      "('The invention relates to an RNA comprising at least one open reading frame '\n",
      " '(ORF) and comprising at least one modification, which increases the '\n",
      " 'expression of the encoded peptide or protein. Furthermore, the invention '\n",
      " 'relates to the medical use of such a modified RNA administered to a subject '\n",
      " 'by jet injection. The invention relates further to a pharmaceutical '\n",
      " 'composition and to a kit of parts comprising said modified RNA for '\n",
      " 'administration by jet injection, preferably for use in the field of gene '\n",
      " 'therapy and/or genetic vaccination. Additionally, the invention relates to a '\n",
      " 'method for enhancing the (localized) expression of RNA-encoded peptides or '\n",
      " 'proteins in the dermis or muscle (of a mammal) comprising administering the '\n",
      " 'modified RNA by jet injection. And finally, the invention relates to a '\n",
      " 'method of treatment comprising administering the modified RNA by jet '\n",
      " 'injection to a subject in need thereof.')\n",
      "\n",
      "========================================\n",
      "\n",
      "('Lipid-protein-sugar particles (LPSPs) are provided as a vehicle for the '\n",
      " 'delivery of nucleic acids. Any polynucleotide (e.g., DNA, RNA) may be '\n",
      " 'encapsulated in a lipid-protein-sugar matrix to form microparticles. '\n",
      " 'Preferably the diameter of the LPSP ranges from 50 nm to 10 micrometers. The '\n",
      " 'particles may be prepared using any known lipid (e.g., DPPC), protein (e.g., '\n",
      " 'albumin), or sugar (e.g., lactose). Methods of preparing the particles and '\n",
      " 'administering the particles for gene therapy are also provided. Preferably '\n",
      " 'the methods of preparing the LPSPs do not significantly damage the '\n",
      " 'polynucleotide to be delivered.')\n",
      "\n",
      "========================================\n",
      "\n",
      "('The present invention relates to a vaccine, especially a combination vaccine '\n",
      " 'providing at least a first and a second antigenic function, the combination '\n",
      " 'vaccine comprising at least one RNA encoding at least one or more proteins '\n",
      " 'or fragments, variants or derivatives of proteins awarding antigenic '\n",
      " 'function, wherein the first antigenic function being a Fusion (F) protein or '\n",
      " 'a fragment, variant or derivative of a Fusion (F) protein derived from the '\n",
      " 'virus family Paramyxoviridae and the second antigenic function being an '\n",
      " 'Hemagglutinin (HA) protein or a fragment, variant or derivative of an '\n",
      " 'Hemagglutinin (HA) protein derived from the virus family Orthomyxoviridae. '\n",
      " 'Furthermore, the present invention is directed to a kit or kit of parts '\n",
      " 'comprising the components of said combination vaccine and to said '\n",
      " 'combination vaccine for use in a method of prophylactic or therapeutic '\n",
      " 'treatment of diseases, particularly in the prevention or treatment of '\n",
      " 'infectious diseases like RSV and influenza.')\n",
      "\n",
      "========================================\n",
      "\n",
      "('The present invention relates to a composition comprising at least one mRNA '\n",
      " 'encoding a combination of antigens capable of eliciting an (adaptive) immune '\n",
      " 'response in a mammal, wherein the antigens are selected from the group '\n",
      " 'consisting of 5T4 (Trophoblast glycoprotein, TPBG), Survivin (Baculoviral '\n",
      " 'TAP repeat-containing protein 5; BIRC5), NY-ESO-1 (New York esophageal '\n",
      " 'squamous cell carcinoma 1, CTAG1B), MAGE-C1 (Melanoma antigen family C1), '\n",
      " 'MAGE-C2 (Melanoma antigen family C2), and MUC1 (Mucin 1). The invention '\n",
      " 'furthermore relates to a vaccine comprising at least one mRNA encoding such '\n",
      " 'a combination of antigens, and to the use of said composition (for the '\n",
      " 'preparation of a vaccine) and/or of the vaccine for eliciting an (adaptive) '\n",
      " 'immune response for the treatment of lung cancer, preferably of non-small '\n",
      " 'cell lung cancer (NSCLC), and diseases or disorders related thereto. '\n",
      " 'Finally, the invention relates to kits, particularly to kits of parts, '\n",
      " 'containing the composition and/or the vaccine.')\n",
      "\n",
      "========================================\n",
      "\n",
      "('The present invention relates to an mRNA sequence, comprising a coding '\n",
      " 'region, encoding at least one antigenic peptide or protein of Rabies virus '\n",
      " 'or a fragment, variant or derivative thereof. Additionally the present '\n",
      " 'invention relates to a composition comprising a plurality of mRNA sequences '\n",
      " 'comprising a coding region, encoding at least one antigenic peptide or '\n",
      " 'protein of Rabies virus or a fragment, variant or derivative thereof.\\n'\n",
      " 'Furthermore it also discloses the use of the mRNA sequence or the '\n",
      " 'composition comprising a plurality of mRNA sequences for the preparation of '\n",
      " 'a pharmaceutical composition, especially a vaccine, e.g. for use in the '\n",
      " 'prophylaxis or treatment of Rabies virus infections. The present invention '\n",
      " 'further describes a method of treatment or prophylaxis of rabies using the '\n",
      " 'mRNA sequence.')\n",
      "\n",
      "========================================\n",
      "\n",
      "('The present invention relates to a composition comprising at least one mRNA '\n",
      " 'encoding a combination of antigens capable of eliciting an (adaptive) immune '\n",
      " 'response in a mammal, wherein the antigens are selected from the group '\n",
      " 'consisting of PSA (Prostate-Specific Antigen), PSMA (Prostate-Specific '\n",
      " 'Membrane Antigen), PSCA (Prostate Stem Cell Antigen), STEAP (Six '\n",
      " 'Transmembrane Epithelial Antigen of the Prostate), MUC1 (Mucin 1) and PAP '\n",
      " '(Prostatic acid phosphatase). The invention furthermore relates to a vaccine '\n",
      " 'comprising at least one mRNA encoding such a combination of antigens and to '\n",
      " 'the use of said composition (for the preparation of a vaccine) and/or of the '\n",
      " 'vaccine for eliciting an (adaptive) immune response for the treatment of '\n",
      " 'prostate cancer (PCa), preferably of prostate adenocarcinoma, locally '\n",
      " 'limited, locally advanced, metastatic, castration-resistant '\n",
      " '(hormone-refractory), metastatic castration-resistant and non-metastatic '\n",
      " 'castration-resistant prostate cancers, and diseases or disorders related '\n",
      " 'thereto. Finally, the invention relates to kits, particularly to kits of '\n",
      " 'parts, containing the composition and/or the vaccine.')\n",
      "\n",
      "========================================\n",
      "\n",
      "('The present invention relates to an mRNA sequence, comprising a coding '\n",
      " 'region, encoding at least one antigenic peptide or protein of RSV infections '\n",
      " 'Respiratory syncytial virus (RSV) or a fragment, variant or derivative '\n",
      " 'thereof. Additionally the present invention relates to a composition '\n",
      " 'comprising a plurality of mRNA sequences comprising a coding region, '\n",
      " 'encoding at least one antigenic peptide or protein of RSV infections '\n",
      " 'Respiratory syncytial virus (RSV) or a fragment, variant or derivative '\n",
      " 'thereof. Furthermore it also discloses the use of the mRNA sequence or the '\n",
      " 'composition comprising a plurality of mRNA sequences for the preparation of '\n",
      " 'a pharmaceutical composition, especially a vaccine, e.g. for use in the '\n",
      " 'prophylaxis or treatment of RSV infections Respiratory syncytial virus (RSV) '\n",
      " 'infections. The present invention further describes a method of treatment or '\n",
      " 'prophylaxis of RSV infections using the mRNA sequence.')\n",
      "\n",
      "========================================\n",
      "\n",
      "('The invention relates to an artificial nucleic acid molecule comprising at '\n",
      " \"least one open reading frame and at least one 3'-untranslated region element \"\n",
      " \"(3'-UTR element) and/or at least one 5'-untranslated region element (5'-UTR \"\n",
      " \"element), wherein the at least one 3'-UTR element and/or the at least one \"\n",
      " \"5'-UTR element prolongs and/or increases protein production from said \"\n",
      " \"artificial nucleic acid molecule and wherein the at least one 3'-UTR element \"\n",
      " \"and/or the at least one 5'-UTR element is derived from a stable mRNA. The \"\n",
      " 'invention further relates to the use of such an artificial nucleic acid '\n",
      " 'molecule in gene therapy and/or genetic vaccination. Furthermore, methods '\n",
      " \"for identifying a 3'-UTR element and/or a 5'-UTR derived from a stable mRNA \"\n",
      " 'element are disclosed.')\n",
      "\n",
      "========================================\n",
      "\n",
      "('The present invention provides a method for providing modified mRNAs of '\n",
      " 'reduced immunogenicity and/or immunostimulatory capacity for use in protein '\n",
      " 'replacement therapy. The invention further provides modified mRNAs and '\n",
      " 'pharmaceutical compositions comprising the modified mRNAs according to the '\n",
      " 'invention for use in protein replacement therapy.')\n",
      "\n",
      "========================================\n",
      "\n",
      "('The present invention relates to a method for producing a liquid composition '\n",
      " 'comprising a nanoparticle comprising at least one RNA and at least one '\n",
      " 'cationic or polycationic compound, advantageously on a large scale suitable '\n",
      " 'for pharmaceutical applications. The present invention further concerns the '\n",
      " 'use of the inventive method in the manufacture of a medicament or a vaccine. '\n",
      " 'Furthermore, the invention relates to compositions containing the '\n",
      " 'RNA-comprising nanoparticle, and to pharmaceutical compositions comprising '\n",
      " 'the same.')\n",
      "\n",
      "========================================\n",
      "\n",
      "('The present invention is directed to the field of RNA formulation, in '\n",
      " 'particular to lyophilization of RNA. The invention provides a method for '\n",
      " 'lyophilization of RNA. The present invention further concerns a lyophilized '\n",
      " 'composition obtainable by the inventive method, a pharmaceutical '\n",
      " 'composition, a vaccine and a kit or kit of parts. Moreover, the present '\n",
      " 'invention provides a novel use of a lyoprotectant for lyophilizing RNA, the '\n",
      " 'use of the inventive method in the manufacture of a medicament as well as '\n",
      " 'the first and second medical use of the composition obtainable by the '\n",
      " 'inventive method, the pharmaceutical composition, the vaccine or the kit or '\n",
      " 'kit of parts according to the invention.')\n",
      "\n",
      "========================================\n",
      "\n",
      "('The present invention relates to the field of RNA analysis. In particular, '\n",
      " 'the invention concerns the use of a catalytic nucleic acid molecule for the '\n",
      " 'analysis of an RNA molecule. The invention concerns methods for analyzing '\n",
      " 'the 5′ terminal structures of an RNA molecule having a cleavage site for a '\n",
      " 'catalytic nucleic acid molecule. In particular, the invention concerns a '\n",
      " 'method for determining the presence of a cap structure in an RNA molecule '\n",
      " 'having a cleavage site for a catalytic nucleic acid molecule, a method for '\n",
      " 'determining the capping degree of a population of RNA molecules having a '\n",
      " 'cleavage site for a catalytic nucleic acid molecule, a method for '\n",
      " 'determining the orientation of the cap structure in a capped RNA molecule '\n",
      " 'having a cleavage site for a catalytic nucleic acid molecule and a method '\n",
      " 'for determining relative amounts of correctly capped RNA molecules and '\n",
      " 'reverse-capped RNA molecules in a population of RNA molecules, wherein the '\n",
      " 'population comprises correctly capped and/or reverse-capped RNA molecules '\n",
      " 'that have a cleavage site for a catalytic nucleic acid molecule. Moreover, '\n",
      " 'the present invention provides uses of a catalytic nucleic acid molecule.')\n",
      "\n",
      "========================================\n",
      "\n",
      "('A process for producing a powder comprises spray freeze-drying an aqueous '\n",
      " 'solution or suspension comprising a pharmaceutical agent, said solution or '\n",
      " 'suspension having a solids content of 20 % by weight or more. The spray '\n",
      " 'freeze-dried powder may be administered to a subject via a needleless '\n",
      " 'syringe.')\n",
      "\n",
      "========================================\n",
      "\n",
      "('The invention relates to an artificial nucleic acid molecule comprising at '\n",
      " 'least one open reading frame and at least one 3′-untranslated region element '\n",
      " '(3′-UTR element) comprising a nucleic acid sequence which is derived from '\n",
      " 'the 3′-UTR of a FIG4 gene or from a variant of the 3′-UTR of a FIG4 gene. '\n",
      " 'The invention further relates to the use of such an artificial nucleic acid '\n",
      " 'molecule in gene therapy and/or genetic vaccination. Furthermore, the '\n",
      " 'invention relates to the use of a 3′-UTR element comprising a nucleic acid '\n",
      " 'sequence which is derived from the 3′-UTR of a FIG4 gene or from a variant '\n",
      " 'of the 3′-UTR of a FIG4 gene for the stabilization and/or prolongation of '\n",
      " 'protein expression from a nucleic acid sequence comprising such 3′-UTR '\n",
      " 'element.')\n",
      "\n",
      "========================================\n",
      "\n",
      "('The present invention relates to an immobilized poly(N)polymerase (PNP), '\n",
      " 'methods of producing said PNP and uses thereof. Further disclosed is an '\n",
      " 'enzyme reactor and kit comprising the PNP for producing polynucleotidylated '\n",
      " 'ribonucleic acid (poly(N)RNA)molecules which are useful in gene therapy, '\n",
      " 'immunotherapy, protein replacement therapy and/or vaccination.')\n",
      "\n",
      "========================================\n",
      "\n",
      "('The present invention relates to a method for in vitro transcription of a '\n",
      " 'linear template DNA which is produced using an immobilized restriction '\n",
      " 'endonuclease. The invention also relates to mutated restriction enzymes '\n",
      " 'which are suitable for immobilization and a solid support to which these '\n",
      " 'restriction enzymes are immobilized. Further, the present invention relates '\n",
      " 'to an enzyme reactor containing said immobilized restriction endonuclease '\n",
      " 'which enzyme reactor can be used for preparing linearized template DNA. '\n",
      " 'Finally, the present invention relates to the use of said enzyme reactor for '\n",
      " 'preparing a linear template DNA for in vitro transcription.In addition, the '\n",
      " 'present invention relates to a kit comprising the immobilized restriction '\n",
      " 'endonuclease.')\n",
      "\n",
      "========================================\n",
      "\n",
      "('The present invention relates to a method for producing RNA. In particular, '\n",
      " 'the present invention relates to a method for producing RNA, which is '\n",
      " 'scalable and provides RNA at a high purity. The present invention provides a '\n",
      " 'method for producing RNA under GMP and/or cGMP-compliant conditions. The '\n",
      " 'invention further provides specific processes for use as a quality control '\n",
      " 'in the manufacturing of a template DNA and/or in a method for producing RNA, '\n",
      " 'in particular by in vitro transcription.')\n",
      "\n",
      "========================================\n",
      "\n",
      "('The present invention relates to RNA containing compositions for use in the '\n",
      " 'treatment or prophylaxis of tumor and/or cancer diseases, to a '\n",
      " 'pharmaceutical composition, to a kit and to uses of the RNA containing '\n",
      " 'compositions for the treatment or prophylaxis of tumor and/or cancer '\n",
      " 'diseases.')\n",
      "\n",
      "========================================\n",
      "\n",
      "('The present invention is directed to a storage-stable formulation of '\n",
      " 'long-chain RNA. In particular, the invention concerns a dry powder '\n",
      " 'composition comprising a long-chain RNA molecule. The present invention is '\n",
      " 'furthermore directed to methods for preparing a dry powder composition '\n",
      " 'comprising a long-chain RNA molecule by spray-freeze drying. The invention '\n",
      " 'further concerns the use of such a dry powder composition comprising a long- '\n",
      " 'chain RNA molecule in the preparation of pharmaceutical compositions and '\n",
      " 'vaccines, to a method of treating or preventing a disorder or a disease, to '\n",
      " 'first and second medical uses of such a dry powder composition comprising a '\n",
      " 'long-chain RNA molecule and to kits, particularly to kits of parts, '\n",
      " 'comprising such a dry powder composition comprising a long-chain RNA '\n",
      " 'molecule.')\n",
      "\n",
      "========================================\n",
      "\n",
      "('The present invention is directed to a storage-stable formulation of '\n",
      " 'long-chain RNA. In particular, the invention concerns a dry powder '\n",
      " 'composition comprising a long-chain RNA molecule. The present invention is '\n",
      " 'furthermore directed to methods for preparing a dry powder composition '\n",
      " 'comprising a long-chain RNA molecule by spray-drying. The invention further '\n",
      " 'concerns the use of such a dry powder composition comprising a long- chain '\n",
      " 'RNA molecule in the preparation of pharmaceutical compositions and vaccines, '\n",
      " 'to a method of treating or preventing a disorder or a disease, to first and '\n",
      " 'second medical uses of such a dry powder composition comprising a long-chain '\n",
      " 'RNA molecule and to kits, particularly to kits of parts, comprising such a '\n",
      " 'dry powder composition comprising a long-chain RNA molecule.')\n",
      "\n",
      "========================================\n",
      "\n",
      "('The present invention relates to prime-boost regimens that involve the '\n",
      " 'administration of at least one mRNA construct, such as the use of such '\n",
      " 'constructs in \"boost\" administration subsequently to \"prime\" administration '\n",
      " 'of certain other antigenic composition(s). Such inventive regimens may, in '\n",
      " 'particular, be useful for the induction of an immune response in a subject, '\n",
      " 'and/or the vaccination of such subject against infection from one or more '\n",
      " 'pathogens, and/or the treatment or prevention of one or more diseases or '\n",
      " 'conditions, including a tumour or cancer, allergy or autoimmune conditions, '\n",
      " 'and/or a disease or condition associated with infection from a pathogen. The '\n",
      " 'present invention further describes methods, uses, vaccination compositions, '\n",
      " 'kits and packaged vaccine components related to or useful for one or more of '\n",
      " 'such regimens.')\n",
      "\n",
      "========================================\n",
      "\n",
      "('The present invention relates to method for producing and purifying RNA '\n",
      " 'comprising the steps of providing DNA encoding the RNA; transcription of the '\n",
      " 'DNA into RNA; and conditioning and/or purifying of the solution comprising '\n",
      " 'transcribed RNA by one or more steps of tangential flow filtration (TFF).')\n",
      "\n",
      "========================================\n",
      "\n",
      "('The present invention relates to an immobilized capping enzyme, preferably '\n",
      " 'an immobilized Vaccinia\\n'\n",
      " 'virus capping enzyme. Furthermore, the present invention relates to an '\n",
      " \"immobilized cap-specific nucleoside 2'-O-methyltransferase, preferably an \"\n",
      " \"immobilized Vaccinia virus cap-specific nucleoside 2'-O-methyltransferase. \"\n",
      " 'Moreover, the present invention relates to a method for immobilizing said '\n",
      " \"enzymes and to a method of using said enzymes for the addition of a 5'-cap \"\n",
      " 'structure to RNAs. Moreover, the present invention relates to an enzyme '\n",
      " 'reactor for performing the capping reaction using said immobilized enzymes '\n",
      " \"and the subsequent separation of the 5'-capped RNA product. In addition, the \"\n",
      " 'present invention relates to a kit comprising the capping enzyme and/or the '\n",
      " \"cap-specific nucleoside 2'-O- methyltransferase.\")\n",
      "\n",
      "========================================\n",
      "\n",
      "('A method of preparing a pharmaceutical composition is described, comprising '\n",
      " '(1) atomizing a liquid formulation of a therapeutic agent to produce an '\n",
      " 'atomized formulation; (2) freezing said atomized formulation to form solid '\n",
      " 'particles; and (3) drying said solid particles at about atmospheric pressure '\n",
      " 'to produce a powder, wherein said drying is performed in the presence of '\n",
      " 'vibration, internals, mechanical stirring, or a combination thereof. Another '\n",
      " 'method is described, comprising (1) atomizing a liquid formulation of a '\n",
      " 'therapeutic agent to produce an atomized formulation; (2) freezing said '\n",
      " 'atomized formulation to form solid particles; and (3) drying said solid '\n",
      " 'particles to produce a powder; wherein the atomized formulation comprises '\n",
      " 'droplets having an average mean diameter of between about 35 and about 300m, '\n",
      " 'and/or the powder comprises dried particles having an average mean diameter '\n",
      " 'of between about 35m and about 300m. Compositions made by the above methods, '\n",
      " 'and methods of using the compositions, are also described.')\n",
      "\n",
      "========================================\n",
      "\n",
      "('A composition or combination comprising at least a first immunogenic '\n",
      " 'component and at least a second adjuvant component, wherein the first '\n",
      " 'immunogenic component comprises at least one nucleic acid molecule encoding '\n",
      " 'at least one epitope of at least one antigen, and wherein the second '\n",
      " 'adjuvant component comprises at least one immune potentiator compound and/or '\n",
      " 'at least one delivery system compound.')\n",
      "\n",
      "========================================\n",
      "\n",
      "('The present invention relates to the field of RNA analysis. In particular, '\n",
      " 'the invention concerns the use of a catalytic nucleic acid molecule for the '\n",
      " 'analysis of an RNA molecule and/or of a population of RNA molecules. In one '\n",
      " 'aspect, the invention concerns methods for analyzing RNA molecules having at '\n",
      " 'least one cleavage site for at least one catalytic nucleic acid molecule. In '\n",
      " 'particular, the invention concerns a method for determining a physical '\n",
      " \"property of an RNA molecule by analyzing a 5' terminal fragment, a 3' \"\n",
      " 'terminal fragment and/or at least one optional central RNA fragment obtained '\n",
      " 'by cleavage of the RNA molecule by at least one catalytic nucleic acid '\n",
      " 'molecule. Moreover, the present invention provides novel uses of a catalytic '\n",
      " 'nucleic acid molecule for analyzing RNA molecules. In particular, the '\n",
      " 'invention relates to the use of a catalytic nucleic acid molecule in a '\n",
      " \"method for analyzing RNA molecules, wherein the resulting 5' terminal RNA \"\n",
      " \"fragment, the 3' terminal RNA fragment and/or the at least one optional \"\n",
      " 'central RNA fragment are analyzed.')\n",
      "\n",
      "========================================\n",
      "\n",
      "('The present invention relates to a vaccine/agonist combination comprising an '\n",
      " 'RNA vaccine comprising at least one RNA comprising at least one open reading '\n",
      " 'frame (ORF) coding for at least one antigen and a composition comprising at '\n",
      " 'least one OX40 agonist. The present invention furthermore relates to a '\n",
      " 'pharmaceutical composition and a kit of parts comprising the components of '\n",
      " 'such a vaccine/agonist combination. Additionally the present invention '\n",
      " 'relates to medical use of such a vaccine/agonist combination, the '\n",
      " 'pharmaceutical composition and the kit of parts comprising such a '\n",
      " 'vaccine/agonist combination, particularly for the prevention or treatment of '\n",
      " 'tumor or cancer diseases or infectious diseases. Furthermore, the present '\n",
      " 'invention relates to the use of an RNA vaccine in therapy in combination '\n",
      " 'with an OX40 agonist.')\n",
      "\n",
      "========================================\n",
      "\n",
      "('The present invention is concerned with a method of producing a target RNA '\n",
      " 'using a circular DNA, wherein said method does not comprise a step of '\n",
      " 'linearizing said circular DNA. The present invention further relates to a '\n",
      " 'circular DNA comprising an RNA polymerase promoter sequence, followed by a '\n",
      " 'sequence encoding a target RNA, followed by a sequence encoding a '\n",
      " 'self-cleaving ribozyme, followed by an RNA polymerase terminator sequence '\n",
      " 'element, wherein the latter element may comprise several RNA polymerase '\n",
      " 'terminator sequences. Multimeric DNA obtained by rolling circle '\n",
      " 'amplification of said circular DNA is also within the scope of the present '\n",
      " 'invention.')\n",
      "\n",
      "========================================\n",
      "\n",
      "('The invention relates to an artificial nucleic acid molecule comprising at '\n",
      " 'least one open reading frame and at least one 3′-untranslated region element '\n",
      " '(3′-UTR) element comprising a nucleic acid sequence which is derived from '\n",
      " 'the 3′-UTR of a ribosomal protein gene. The invention further relates to the '\n",
      " 'use of such an artificial nucleic acid molecule in gene therapy and/or '\n",
      " 'genetic vaccination. Furthermore, the invention relates to the use of a '\n",
      " '3′-UTR element comprising a nucleic acid sequence which is derived from the '\n",
      " '3′-UTR of a ribosomal protein gene for enhancing, stabilizing and/or '\n",
      " 'prolonging protein expression from a nucleic acid sequence comprising such '\n",
      " '3′-UTR element.')\n",
      "\n",
      "========================================\n",
      "\n",
      "('The invention concerns the field of genetic vaccination, in particular RNA '\n",
      " 'vaccines. The present invention provides an mRNA for use in the treatment '\n",
      " 'and/or prevention of a disease, wherein the mRNA is administered to the '\n",
      " 'epidermis. Furthermore, the invention provides compositions comprising the '\n",
      " 'mRNA for epidermal administration or kits comprising the mRNA for epidermal '\n",
      " 'administration. Moreover, the invention concerns the medical use of the mRNA '\n",
      " 'or compositions comprising the mRNA, wherein the mRNA or compositions '\n",
      " 'comprising the mRNA are administered to the epidermis.')\n",
      "\n",
      "========================================\n",
      "\n",
      "('The present invention is directed to a storage-stable formulation of '\n",
      " 'long-chain RNA. In particular, the invention concerns a dry powder '\n",
      " 'composition comprising a long-chain RNA molecule. The present invention is '\n",
      " 'furthermore directed to methods for preparing a dry powder composition '\n",
      " 'comprising a long-chain RNA molecule by spray-drying. The invention further '\n",
      " 'concerns the use of such a dry powder composition comprising a long-chain '\n",
      " 'RNA molecule in the preparation of pharmaceutical compositions and vaccines, '\n",
      " 'to a method of treating or preventing a disorder or a disease, to first and '\n",
      " 'second medical uses of such a dry powder composition comprising a long-chain '\n",
      " 'RNA molecule and to kits, particularly to kits of parts, comprising such a '\n",
      " 'dry powder composition comprising a long-chain RNA molecule.')\n",
      "\n",
      "========================================\n",
      "\n",
      "('The present invention is directed to a storage-stable formulation of '\n",
      " 'long-chain RNA. In particular, the invention concerns a dry powder '\n",
      " 'composition comprising a long-chain RNA molecule. The present invention is '\n",
      " 'furthermore directed to methods for preparing a dry powder composition '\n",
      " 'comprising a long-chain RNA molecule by spray-freeze drying. The invention '\n",
      " 'further concerns the use of such a dry powder composition comprising a '\n",
      " 'long-chain RNA molecule in the preparation of pharmaceutical compositions '\n",
      " 'and vaccines, to a method of treating or preventing a disorder or a disease, '\n",
      " 'to first and second medical uses of such a dry powder composition comprising '\n",
      " 'a long-chain RNA molecule and to kits, particularly to kits of parts, '\n",
      " 'comprising such a dry powder composition comprising a long-chain RNA '\n",
      " 'molecule.')\n",
      "\n",
      "========================================\n",
      "\n"
     ]
    }
   ],
   "source": [
    "# dir_files = os.listdir(\"results\")\n",
    "dir_files = os.listdir(r\"C:\\Users\\Asus\\OneDrive\\Desktop\\AI Agents Projects\\results\")\n",
    "\n",
    "\n",
    "for file in dir_files:\n",
    "    if file.endswith('.json'):\n",
    "        with open(os.path.join(r\"C:\\Users\\Asus\\OneDrive\\Desktop\\AI Agents Projects\\results\",file),\"r\") as f:\n",
    "            content = json.load(f)\n",
    "            pprint(content.get(\"abstract\",\"\"))\n",
    "            print(\"\\n\" + \"=\"*40 + \"\\n\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 22,
   "id": "f499848f",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "c:\\Users\\Asus\\OneDrive\\Desktop\\AI Agents Projects\\aigent\n"
     ]
    }
   ],
   "source": [
    "import os\n",
    "print(os.getcwd())\n",
    "  "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "id": "c2c9c180",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "embedding dimensions: 768\n"
     ]
    }
   ],
   "source": [
    "emb_url = \"http://localhost:11434/api/embeddings\"\n",
    "\n",
    "headers = {\n",
    "    \"Content-Type\":\"application/json\",\n",
    "}\n",
    "\n",
    "data = {\n",
    "    \"model\": \"nomic-embed-text\",\n",
    "  \"prompt\": \"The sky is blue because of Rayleigh scattering\"\n",
    "}\n",
    "\n",
    "response = requests.post(emb_url,headers=headers,json=data )\n",
    "response_data = response.json()\n",
    "\n",
    "if response.status_code == 200:\n",
    "    embed = response_data.get(\"embedding\")\n",
    "    print(\"embedding dimensions:\",len(embed))\n",
    "    # pprint(response_data)\n",
    "#     embeddings = response.json().get('embeddings',[])\n",
    "#     print(\"Embeddings:\")\n",
    "#     for emb in embeddings:\n",
    "#         print(emb)\n",
    "# else:\n",
    "#     print(\"Error: {response.status_code}, {response.text}\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "b0eb67ac",
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "aigent (3.13.5)",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.13.5"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
